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Abstract 
 
Malaria is an infectious disease transmitted by Anopheles mosquitoes and 
caused by protozoan parasites of the genus Plasmodium. Despite countless efforts, 
there is still no effective vaccine against any of the human infective Plasmodium 
parasites of which P. falciparum and P. vivax are the most clinically significant.  
A new whole organism-vaccine has been proposed which is based on the use 
of genetically modified rodent parasites (P. berghei) as platforms for the delivery of 
immunogenic antigens of human infective Plasmodium species. The efficacy and 
safety of P. berghei parasites as a platform to deliver immunogenic antigens is 
warranted by their ability to infect human hepatocytes without being able to develop 
inside human erythrocytes. A genetically modified P. berghei expressing P. falciparum 
circumsporozoite (CS) protein, under the control of the P. berghei UIS4 promoter, 
(Pb(PfCS@UIS4)), was already developed and characterized as a potential vaccine 
candidate. Immunization of mice with Pb(PfCS@UIS4) parasites has successfully 
elicited an immune response capable to recognize and bind to P. falciparum 
sporozoites, and inhibit infection by this parasite.  
P. vivax malaria is the most widespread of the human-infective Plasmodium 
species and leads to a great socioeconomic burden worldwide. In light of this fact, and 
given the promising results obtained for the vaccine candidate Pb(PfCS@UIS4), a new 
genetically modified P. berghei expressing the P. vivax CS protein, Pb(PvCS@UIS4) 
was created, as a vaccine candidate against P.vivax malaria. This parasite was 
generated using the GIMO (Gene Insertion Marker Out) transfection method. 
 The work presented in this thesis aims to characterize Pb(PvCS@UIS4) 
parasites in terms of infectivity and development across the sporogonic and pre-
erythrocytic stages of the parasite life cycle, both in vitro and in vivo. Sporogonic 
parasite development and infectivity in the mosquito was assessed using Anopheles 
stephensi mosquitoes by counting oocysts in the midgut and sporozoites in the salivary 
glands at 10 and 21 days post infectious blood meal, respectively. No significant 
differences were observed between the development of Pb(PvCS@UIS4) and PbGIMO 
(wild-type P. berghei - transfection motherline) parasites. Pre-erythrocytic development 
was evaluated in vitro on Huh7 and HepG2 human hepatoma cell lines (48h p.i) and in 
vivo experiments on C57BL/6J mice (44 hpi), revealing that Pb(PvCS@UIS4) 
sporozoites can infect and develop within hepatocytes to a similar extent to PbGIMO 
sporozoites. Blood stage development experiments also revealed that 
Pb(PvCS@UIS4) parasites infectivity and development during this stage is comparable 
to PbGIMO. These results indicate that the insertion of the PvCS gene in P. berghei 
230p neutral locus does not appear to have an impact on the parasite‟s ability to infect 
and develop throughout its life cycle. Additionally, CS expression was also assessed 
on Pb(PvCS@UIS4) sporozoites and exoerythrocytic forms (intrahepatic forms of the 
parasite), showing that both the endogenous PbCS and the exogenous PvCS are 
indeed being co-expressed on both stages. 
This characterization represents one of the first steps on the development of 
this new vaccine candidate against P.vivax malaria and the results here presented 
 
 
 
 
provide valuable insight in order to proceed to future studies regarding the 
immunogenicity and efficacy of Pb(PvCS@UIS4) as a vaccine candidate. 
 
Keywords: Malaria, Plasmodium vivax, Plasmodium berhgei, whole-organism vaccine, 
transgenic, circumsporozoite protein.
 
 
 
 
Resumo 
 
A malária é uma doença infecciosa causada por um parasita protozoário do 
género Plasmodium que causa a morte entre 650.000 a 1.200.000 pessoas todos os 
anos, das quais aproximadamente 85% são crianças com menos de 5 anos de idade.1 
Existem 5 espécies de Plasmodium capazes de causar malária em humanos, sendo P. 
falciparum e P. vivax as espécies responsáveis pela grande maioria dos casos.1 Estes 
parasitas são transmitidos sob a forma de esporozoíto através da picada de mosquitos 
fêmea do género Anopheles.1 Após a picada, os esporozoítos invadem a corrente 
sanguínea do hospedeiro e migram até ao fígado onde, após atravessarem vários 
hepatócitos, acabam por invadir e se desenvolver dentro de um.10,11 No interior do 
hepatócito, o parasita replica-se, dando a origem a milhares de merozoítos.12 Estes 
são libertados para a corrente sanguínea no interior de uma estrutura denominada 
merosoma, terminando assim a fase pré-eritrocitária da infeção.10 Uma vez na corrente 
sanguínea, o merosoma rompe-se e liberta os merozoítos que por sua vez vão infetar 
os eritrócitos, dando origem à fase sanguínea e sintomática da doença.10 Dentro dos 
eritrócitos os parasitas vão novamente replicar-se, dando origem a novos parasitas 
capazes de perpetuar o ciclo de infeção na corrente sanguínea mas dando igualmente 
origem a formas sexuais (gametócitos) aptas para serem ingeridas aquando da picada 
por novos mosquitos e de se desenvolverem dentro dos mesmos, dando origem a um 
novo ciclo de infeção.13 Apesar da malária causada por P. falciparum ter uma 
sintomatologia mais severa, a malária causada por P. vivax tem uma maior distribuição 
geográfica e está geralmente associada a longos períodos de morbilidade devido à 
capacidade que o parasita possui de gerar formas adormecidas (hipnozoítos), que 
podem levar a uma reincidência dos sintomas da doença.5,6 
Atualmente, as medidas de combate à malária passam pelo uso de inseticidas 
para diminuir as populações de mosquitos transmissores, uso de redes mosquiteiras e 
a prescrição de fármacos profiláticos contra a malária. No entanto, a eficácia tanto dos 
inseticidas como dos fármacos tem vindo a diminuir ao longo do tempo devido ao 
aparecimento de “perfis” de resistência quer nas populações de mosquitos contra os 
inseticidas, quer nas populações de Plasmodium contra os fármacos existentes.1,15,17 
Dadas as limitações das medidas existentes, tornou-se consensual entre a 
comunidade científica de que a criação de uma vacina é uma componente essencial 
no combate à malária, uma vez que esta permitiria não apenas prevenir a 
sintomatologia da doença mas também a sua transmissão. Contudo, até ao momento 
não existe uma vacina licenciada contra a malária.17 
A RTS,S, a vacina que se encontra actualmente no estadio mais avançado de 
desenvolvimento, é uma vacina de subunidade, que consiste na administração de um 
fragmento da proteína CS do parasita Plasmodium falciparum fundido com uma matriz 
transportadora proveniente da superfície do vírus da hepatite B, mostrou oferecer um 
nível de proteção bastante modesto em humanos.27 Em particular, as respostas 
imunitárias observadas após vacinação com RTS,S foram maioritariamente mediadas 
por células T CD4+ e anticorpos contra a proteína CS, sem que os níveis de células T 
 
 
 
 
CD8+ detectáveis fossem muito significativos, as quais estão demonstradas como 
sendo as principais células efectoras na proteção imunitária contra a malária.22,30,31 
Como alternativa, outros tipos de vacina contra a malária estão a ser 
desenvolvidos, como por exemplo, as vacinas de organismo inteiro. As vacinas de 
organismo inteiro consistem na administração de parasitas inteiros, previamente 
atenuados, com o objetivo de espoletar uma resposta imunitária capaz de inibir a 
infeção causada por organismos não atenuados. Vários estudos realizados com 
esporozoítos atenuados (P. falciparum), têm demonstrado que estas estratégias de 
vacinação podem garantir um alto nível de proteção em humanos.33-35,45 Além disso, as 
respostas espoletadas com esta estratégia de vacinação são maioritariamente 
mediadas por células T CD8+.32 Foi também observado que o nível de proteção é 
tanto maior quanto maior for a progressão do desenvolvimento do parasita no fígado.32 
No entanto, estas vacinas baseiam-se na assunção que todos os parasitas 
administrados estão totalmente atenuados, e como tal, não progridem para a fase 
sanguínea da infeção. Dito isto, é fácil perceber que este princípio representa um risco 
para os indivíduos vacinados, uma vez que basta que um parasita escape ao processo 
de atenuação, para que haja progressão da infeção para a fase sintomática da 
doença. 
Como resposta a esta limitação inerente às vacinas que se baseiam no uso de 
parasitas atenuados, a equipa do Prudêncio Lab no IMM está a desenvolver uma nova 
estratégia de vacinação que se baseia no uso de parasitas de roedores (P. berghei) 
geneticamente modificados, como plataforma de apresentação de antigénios 
pertencentes às espécies de Plasmodium que causam malária em humanos, de forma 
a promover imunidade contra os mesmos quer por mecanismos de proteção cruzada 
entre espécies quer por mecanismos de proteção especifica contra os antigénios dos 
parasitas causadores de malária em humanos. 
Com o intuito validar esta nova estratégia, foram realizadas experiências no 
sentido de verificar que P. berghei consegue invadir e desenvolver-se em hepatócitos 
humanos sem progredir para a fase sanguínea, e que parasitas P. berghei 
geneticamente modificados para expressar a proteína CS de P. falciparum, são 
capazes de espoletar respostas imunológicas capazes de reconhecer e inibir P. 
falciparum. Foi então desenvolvido e caracterizado um novo candidato a vacina, que 
consiste em usar P. berghei geneticamente modificado de forma a que este expresse 
a proteína CS de P. falciparum sob o controlo do promotor UIS4 de P. berghei, o 
parasita Pb(PfCS@UIS4).  
Os resultados deste estudo demonstraram que P. berghei consegue de facto 
infetar hepatócitos humanos sem causar doença, o que faz deste parasita uma 
potencial plataforma de administração de antigénios imunogénicos para humanos. Por 
outro lado, a imunização de ratinhos com Pb(PfCS@UIS4) mostrou conduzir a 
respostas imunitárias capazes de reconhecer e ligar-se a esporozoítos de P. 
falciparum, inibindo a infeção por este parasita. 
Dados os resultados satisfatórios obtidos com a caracterização do parasita 
Pb(PfCS@UIS4), foi produzido um novo candidato a vacina contra P. vivax, o parasita 
Pb(PvCS@UIS4), que de um modo semelhante ao candidato anterior, consiste em 
 
 
 
 
usar P. berghei geneticamente modificado de forma a expressar a proteína CS de 
P.vivax sob o controle do promotor UIS4 de P. berghei. 
Deste modo, esta tese de mestrado teve como objetivo principal caracterizar o 
desenvolvimento deste novo parasita durante o seu ciclo de vida dentro do mosquito 
assim como caracterizar a sua infetividade e desenvolvimento em culturas celulares in 
vitro, e in vivo com ratinhos C57BL/6J. Adicionalmente, a sequência do gene PvCS 
usada na criação deste parasita foi analisada em detalhe e comparada com 
sequências referencia para o mesmo gene disponíveis na base de dados PlasmoDB 
de modo a identificar diferenças significativas entre a sequência encontrada no isolado 
de P. vivax utilizado e as diferentes populações existentes mundialmente. Ao 
compararmos a sequencia da PvCS usada na criação do Pb(PvCS@UIS4) com as 
sequencias existentes na base de dados, concluímos que as regiões N-terminal e C-
terminal da proteína se mantêm conservadas, enquanto que na zona “central de 
repetição”, existe alguma variabilidade. De acordo com estudos anteriores, concluímos 
que a variabilidade encontrada no nosso isolado não é superior à que normalmente se 
verifica para este gene e que as alterações especificas encontradas são muito 
provavelmente características comuns das populações de P. vivax existentes na 
região geográfica de onde foi obtido o isolado utilizado neste estudo (Tailândia).47,51 
De forma a caracterizar o desenvolvimento dos parasitas Pb(PvCS@UIS4) 
dentro do mosquito, foram contados quer os oocistos presentes no estômago do 
mosquito ao dia 10 após infeção quer esporozoítos presentes nas glândulas salivares 
entre o dia 20 e 22 após infeção. Estes números foram então comparados com os 
números obtidos com parasitas não-transfetados, pertencentes à linha mãe (PbGIMO) 
usada na transfeção dos parasitas Pb(PvCS@UIS4). Os resultados mostraram que 
não existem diferenças significativas entre os parasitas Pb(PvCS@UIS4) e PbGIMO, o 
que nos leva a concluir que a inserção da PvCS não aparenta ter qualquer impacto 
nesta fase de desenvolvimento do parasita. 
A fim de caracterizar a capacidade deste parasita se desenvolver e invadir 
células in vitro, foram usadas 2 linhas celulares de hepatomas humanos; Huh7 e 
HepG2. Estas linhas celulares foram infetadas com esporozoítos recolhidos das 
glândulas salivares de mosquitos infetados a partir do dia 20 após infeção. Passadas 
48h da infeção, as células foram fixadas e marcadas com anticorpos de marcação 
nuclear e anticorpos específicos contra o parasita (anti-HSP70). Desta forma, através 
de microscopia de fluorescência, foi quantificado o nível de infeção e comparado entre 
parasitas Pb(PvCS@UIS4) e PbGIMO. Não foram observadas diferenças significativas 
entre os níveis de infeção observados com ambos os parasitas, o que demonstra que 
o desenvolvimento do parasita na fase hepática não é afetado pela presença da 
proteína CS exógena. Resultados idênticos foram também obtidos in vivo, em 
experiencias em que ratinhos C57BL/6J foram infetados por injeção i.v. de 
esporozoítos. Nestas experiencias, decorridas 44h após a infeção, os ratinhos foram 
sacrificados e os seus fígados foram recolhidos de forma a ser possível analisar os 
níveis de infeção por qRT-PCR e microscopia de imunofluorescência. 
Concomitantemente com as experiencias anteriores, a expressão da PbCS e 
da PvCS foi também observada com recurso a técnicas de microscopia de 
imunofluorescência. Como era esperado, nos parasitas Pb(PvCS@UIS4), a PbCS e a 
 
 
 
 
PvCS estão a ser co-expressas em esporozoítos e nas formas exoeritrocitárias 
presentes em hepatócitos infetados. Esta observação é extremamente relevante para 
a estratégia de vacinação, uma vez que é esperado que parte da imunidade gerada 
seja especificamente contra a PvCS. 
Para terminar a caracterização dos parasitas Pb(PvCS@UIS4), foi também 
realizada uma experiencia no sentido de caracterizar a capacidade destes parasitas 
infetarem e se desenvolverem durante a fase eritrocitária da doença ao longo de 9 
dias após infeção. Os resultados demonstraram que não existem diferenças 
significativas entre a capacidade de infectar e se replicar no interior dos eritrócitos por 
parte dos parasitas Pb(PvCS@UIS4) quando comparados com parasitas PbGIMO.  
 Concluindo, os parasitas Pb(PvCS@UIS4) demonstraram não apresentar 
nenhuma  diferença significativa em termos de capacidade infetiva e de 
desenvolvimento ao longo do seu ciclo de vida quando comparados com a linha 
materna usada para transgénese. No contexto de desenvolvimento de uma vacina é 
importante que o parasita mantenha a sua funcionalidade de forma a conseguir 
apresentar o maior número possível de antigénios e desta forma, tornar a vacina mais 
eficaz. Adicionalmente, a PvCS está a ser expressa tanto em esporozoítos como 
durante a fase hepática, o que mais uma vez, no contexto desta estratégia de 
vacinação, é extremamente importante dado que a maior parte da imunidade contra 
Plasmodium é gerada durante a fase hepática. Os resultados aqui obtidos estão em 
concordância com os resultados previamente obtidos com o candidato a vacina contra 
P. falciparum, o Pb(PfCS@UIS4). Os dados aqui apresentados representam um 
primeiro passo na caracterização deste candidato a vacina e, como tal, serão 
necessárias mais experiencias, nomeadamente do ponto de vista imunológico, para 
averiguar a sua eficácia. 
 
Palavras-chave: Malaria, Plasmodium vivax, Plasmodium berhgei, vacinas de 
organismo inteiro, transgenico, Proteina circumsporozoite. 
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Abbreviations 
 
18S Plasmodium 18S ribosomal RNA NK Natural Killer cells 
5-FC 5-fluorocytosine PABA p-aminobenzoic acid 
BSA Bovine serum albumin Pb(PfCS@UIS4) 
Plasmodium berghei expressing 
Plasmodium falciparum 
circumsporozoite protein under 
the control of the 
PbUIS4promoter  
cDNA 
Complementary 
Deoxyribonucleic acid 
Pb(PvCS@UIS4) 
Plasmodium berghei expressing 
Plasmodium vivax 
circumsporozoite protein under 
the control of the 
PbUIS4promoter  
CS Circumsporozoite protein PbCS 
Plasmodium berghei 
circumsporozoite protein 
DMEM 
Dulbecco Modified Eagle‟s 
Medium – cell culture medium 
PbGIMO 
Plasmodium berghei (Gene 
Insertion Marker Out) motherline 
DNA Deoxyribonucleic acid PBS 
Phosphate buffered saline 
solution 
EEF Exoerythrocytic forms PCR/qRT-PCR 
Polymerase chain 
reaction/quantitative real time 
polymerase chain reaction 
ER Endoplasmatic reticulum PfCS 
Plasmodium falciparum 
circumsporozoite protein 
GAP Genetically Attenuated Parasites p.i Post-infection 
GMEP 
Global Malaria Eradication 
Program 
PvCS 
Plasmodium vivax 
circumsporozoite protein 
HC-04 Human hepatocyte cell line PVM 
Parasitophorous vacuole 
membrane 
hdhfr 
Selectable markar human 
dehydrofolate reductase 
RAS Radiation attenuated sporozoites 
HEPES 
4-(2-hydroxyethyl) -1-
piperazineethanesulfonic acid 
RBC Red blood cell 
HepG2 Human hepatoma cell line RNA Ribonucleic acid 
HPRT 
Hypoxanthine Guanine 
Phosphoribosyl Transferase 
RPMI 
Roswell Park Memorial Institute 
medium – cell culture medium 
HSPG Heparin sulphate proteoglycans RPM Rotations per minute 
Huh7 Human hepatoma cell line SEM Standard error of the mean 
IFN-y Interferon gamma STAT 
Signal transducers associated 
with transcription 
iNOS Nitric oxide synthase TSR Thrombospondin repeat region 
i.p. Intraperitoneal WT Wild type 
i.v. Intravenous yfcu Yeast fcu selectable marker 
MHC Major Histocompatibility Complex HSP70 Heat shock protein 70 
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1. Introduction 
1.1 Socioeconomic burden 
Malaria represents one of the most serious public health problems worldwide; 
and although malaria incidence has been decreasing over the past 14 years, every 
year there are more than 216 million clinical episodes resulting in 650.000 to 1.200.000 
deaths, 85% of which occur in children under 5 years old. In 2012 alone, an estimated 
3.4 billion people (47% of the world‟s total population) were at risk of malaria, of which  
1.2 billion, mostly in the African and South-East Asia regions, were at high risk (>1 
case per 1000 population) of contracting this disease.1 Malaria was once present 
worldwide. However, between 1940 and 1969, with the establishment of the Global 
Malaria Eradication Programme (GMEP) by WHO, it was possible to eliminate malaria 
from USA and Canada, Europe, and Russia.2 Nevertheless, the excessive use of 
insecticides and anti-malarial drugs, such as chloroquine, which were the core tools of 
the GMEP, led to a resurgence of malaria prevalence in some tropical countries on the 
following years.3 Additionally, the selective pressure issued by those two factors 
(insecticides and anti-malarials) led to the appearance of insecticide and drug resistant 
mosquito and Plasmodium populations, respectively.3 Nowadays, malaria is still 
present in 104 countries, in which it is considered endemic.1 
1.2 Etiology and distribution 
Malaria is an infectious disease caused by protozoan parasites of the genus 
Plasmodium, which are transmitted by female Anopheles mosquitoes. There are 
numerous species of Plasmodium parasites which can infect a plethora of vertebrate 
animal species, although only five Plasmodium species (P. falciparum, P. vivax, P. 
ovale, P. malariae and P. knowlesi) are known to cause disease in humans.1 P. 
falciparum and P. vivax raise the greatest concerns in terms of public health as the 
remaining three species are reported to have much lower incidence rates.1 P. 
falciparum malaria is indeed the most deadly form of human malaria but it 
predominates mostly in Africa (Fig.1.A); as for P. vivax malaria, although not as severe 
presents a wider distribution (Fig.1.B) ranging from South American to South-eastern 
Asian regions.1 Despite the fact that most malaria-related deaths are due to P. 
falciparum infections, there is no denying the impact of P. vivax infections, mostly 
because P. vivax, unlike P. falciparum, is able to evolve into dormant forms 
(hypnozoites) that can result in disease relapses.4 Relapses associated to P. vivax 
malaria add to the morbidity burden and make this species of Plasmodium even harder 
to eliminate.5 The low transmission of P. vivax in African countries is due to the 
predominantly Duffy negative human populations. The Duffy receptor is a chemokine 
receptor present on the erythrocyte surface of Duffy positive individuals and it is known 
to be essential for P. vivax parasites to recognize and invade erythrocytes.6 Therefore, 
populations with a Duffy negative trait are resistant to P. vivax infections.6 
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Figure 1 – Malaria transmission map – World map showing the areas with P. 
falciparum (top map) and P. vivax malaria transmission. Regions coloured in pink 
represent areas with unstable malaria transmission (annual case incidence 
reported is lower than 0,01%). Regions colored in red represent areas with stable 
malaria transmission (annual case incidence reported is higher than 0,01%).68,69 
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1.3 Symptoms and diagnosis 
The first malaria symptoms usually appear about 7-9 days post infection 
(depending on the Plasmodium species). In endemic areas, malaria is the most 
common cause of fever, although uncomplicated malaria includes other flu-like 
symptoms, such as headache, fatigue, muscle ache, anemia, nausea, and after a few 
days, a palpable spleen.7 Severe malaria may have other manifestations, most 
commonly in children or immunocompromised adult individuals, such as acute 
pulmonary oedema, kidney injury, jaundice, generalized seizures and ultimately coma 
(cerebral malaria).8 
The most common method for malaria diagnosis is by the microscopic 
observation of Giemsa-stained blood films. However, depending on resource 
availability, there are other methods such as antigen detection kits or by polymerase 
chain reaction (PCR).9 
1.4 Plasmodium life cycle 
Female Anopheles mosquitoes regularly bite mammalian hosts to take a blood 
meal and gather the required proteins to generate eggs. During a bite, the mosquito 
injects saliva in order to generate an anesthetic, vasodilator and anti-coagulant effect.10 
When a mosquito is infected, a Plasmodium form called sporozoite migrates to the 
mosquito‟s salivary glands and, upon a blood meal, will be injected into the host‟s skin 
(Fig.2.1).11 Some of the injected parasites will use gliding motility to move to the 
nearest blood vessel and enter the bloodstream. Upon reaching the bloodstream, 
sporozoites remain in circulation until they eventually reach the liver sinusoids, where 
they traverse endothelial, Kupffer cells and a few hepatocytes until productively 
infecting a final hepatocyte (Fig.2.2). When hepatocyte infection occurs, sporozoites 
will form a parasitophorous vacuole and, within it, transform into spherical hepatic 
stages called exoerythrocytic forms – EEFs.12 P. vivax and P. ovale parasites can 
develop into dormant hepatic forms (hypnozoites) that can be reactivated later and 
proceed with the normal course of infection (Fig.2.3). Parasites multiply inside the cell, 
ultimately forming a schizont, which is made up of thousands of merozoites (Fig.2.4).10 
After the process of maturation, merozoites are released inside merosomes, which 
eventually burst and release the merozoites to the bloodstream where they will infect 
erythrocytes (Fig.2.5). Inside the erythrocytes, making use of the infected cell‟s 
resources, more merozoites will develop. After reaching erythrocyte capacity, the cell 
will burst and release all the merozoites into the bloodstream, leading to the symptoms 
of malaria (Fig.2.6).10 In some cases, infected erythrocytes will lead to the formation of 
gametocytes, the sexual forms of the parasite (Fig.2.7).13The parasite‟s life cycle is 
eventually perpetuated when a new mosquito bites an infected individual and collects 
Plasmodium gametocytes in its blood meal. Upon reaching the mosquito midgut, 
Plasmodium male gametocytes are exposed to mosquito-specific factors and 
environmental factors forming eight motile male gametes (exflagellation) that undergo a 
process of fusion with female gametes leading to a new form, the zygote.13 The zygote 
will mature into a motile ookinete (24h post-blood meal) that will penetrate the midgut 
epithelium, moving from the lumen to the basal side, beginning the transformation into 
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an oocyst (Fig.2.8). Oocyst development takes between 7 and 14 days (depending on 
mosquito-parasite species combination). About 11-18 days after mosquito‟s infection, 
thousands of sporozoites have been produced inside the oocysts (through budding 
process), leading to the oocyst burst and sporozoite release into mosquito‟s 
hemolymph.13 When in the hemolymph, sporozoites will migrate and infect the salivary 
glands along with the formation of a parasitophorous vacuole.10 Sporozoites will then 
be ready to start a new cycle of infection upon the mosquito‟s next blood meal 
(Fig.2.9). 
 
 
 
 
 
 
 
Figure 2 – Plasmodiumspp life cycle – 1 – During the bite of an infected 
mosquito, spozoroites are injected into the host‟s skin. 2 – The sporozoites 
migrate to the liver where they traverse several hepatocytes until effectively 
infecting one. 3 (Only in P. vivax and P. ovale infections) – The parasites inside 
the hepatocyte develop into a dormant form, the hipnozoite. 4 – Merozoites 
replicate inside the hepatocyte, forming a schizont. 5- After finishing the 
development inside the hepatocyte, the merozoites grouped inside the 
merosome, will be released into the blood stream, where the merosome 
membrane will burst releasing the infectious merozoites. 6 – The merozoites will 
infect erythrocytes where they will replicate, leading to the formation of sexual 
(gametocytes) and asexual forms. Asexual forms will then perpetuate the cycle of 
infection inside the host by infecting more erythrocytes. 7 – Gametocytes in 
circulation are taken by uninfected mosquitoes that bite an infected host. 8 – 
Inside the mosquito, a zygote is formed and matured into motile ookinetes which 
will invade the midgut epithelium and develop into oocysts. As oocysts mature, 
sporozoites are formed within. When sporozoite‟s development is complete the 
oocyst will burst and the sporozoites will migrate to the mosquito salivary glands.  
9 – The mosquito will infect a new host upon its next blood meal. 
 
 
 
8 
 
 
1.5 Control measures 
Nowadays the most relevant malaria control measures are the use of indoor 
residual spraying to control Anophelian populations, the distribution of insecticide-
treated bednets and the prescription of prophylactic/therapeutic drugs.1 However, the 
efficacy of these measures is dramatically decreasing.14 Specifically, the intensive 
process of positive selection created by the uncontrolled use of insecticides led to the 
appearance of Anophelian populations which are more likely to have multiple 
mechanisms of resistance against common insecticides15, and bednets are insufficient 
since some mosquitoes have peak-biting hours before bedtime.16Likewise, many of the 
existing drugs are becoming ineffective as resistance is developed by Plasmodium 
populations.17 The World Health Organization (WHO) currently recommends 
artemisinin-based combination therapies for uncomplicated P. falciparum malaria. 
Chloroquine, the malaria wonder drug during the 1950s and 1960s, is still a valid option 
for some countries (especially against P. vivax), although with a lower efficacy due to 
chloroquine-resistant Plasmodium profiles.1 
1.6 Vaccines against Malaria 
Given all the limitations associated with vector control measures and anti-
malarial drugs, it became consensual within the malaria scientific community that a 
vaccine will always be an essential component of any malaria eradication/control 
strategy, as it would prevent malaria symptoms from occurring effectively, reducing 
morbidity and mortality on malaria endemic regions.17 For the past 75 years, efforts 
have been made to create a vaccine that would grant immunity against Plasmodium 
parasites, although no licensed vaccine has been developed so far. The main reasons 
for such a delayed progress toward an effective malaria vaccine are the complexity of 
the parasite, its genetic diversity, the incomplete and temporary nature of naturally 
acquired immunity and also the fact that parasite material must be obtained from 
infected hosts or mosquitoes, as only P. falciparum can be grown in continuous 
culture.18 To put all its complexity into context, the P. falciparum genome has more 
than 23 million bases of DNA organized into 14 chromosomes and about 5.000 genes. 
This is a significantly more complex genome than that of many of the pathogens 
against which vaccines have already been developed.18 Despite all the hardship on 
malaria research, and particularly on malaria vaccine development, in the past couple 
of decades, with the increased funding and the development of new molecular biology 
techniques, there has been an increase of viable vaccine candidates. Malaria vaccines 
can fall into three groups based on their target in the parasite‟s life cycle; blood-stage 
vaccines, transmission-blocking vaccines and pre-erythrocytic vaccines.19 
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1.6.1 Historical background 
The first attempts to generate a malaria vaccine took place during the early 
1930s. These studies used avian animal species as a model and used inactivated, 
killed, whole parasites or parasite extracts as vaccines, often accompanied by immune-
boosting adjuvant systems, though with no success.18 In 1945, Jules Freund reported 
that he had partially protected ducks against intravenous challenge with the avian 
malaria P. lophurae by immunizing them with formalin-inactivated malaria-infected 
blood cells and an adjuvant system consisting of a lanolin-like substance, paraffin oil, 
and killed tubercle bacilli.18 Shortly afterwards, a similar experiment was done with 
Rhesus monkeys and P. knowlesi, also successfully. These initial studies showed that 
whole-organism vaccines appeared to be a good and viable approach and that it is 
important to use good adjuvants to elicit an immune protection against the parasite.18 It 
was only in 1967 that the first successful pre-erythrocytic targeting vaccine was 
reported; Ruth Nussenweig‟s group showed that radiation-attenuated P. berghei 
sporozoites injected intravenously in mice could indeed elicit protective immunity.20 
These findings already suggested that the capacity of the parasite to infect is important 
to elicit protective immunity, as past attempts showed that immunizations with dead 
sporozoites grant no protection against subsequent infections.21 
 
1.6.2 Immunity in Malaria 
 
Despite all the years of human and animal research in malaria, the basis of 
protective immunity against malaria is still poorly understood. However, some recent 
studies have been aiming to establish which specific immune responses have an 
essential role in protective immunity. For a long time, it was believed that the 
mechanism responsible for the protection induced by the radiation-attenuated 
sporozoites was mainly antibody-meadiated.22 Nowadays, not excluding the 
importance of the humoral response, it is commonly accepted that CD8+ T cell specific 
for the parasite-derived peptide/class I MHC molecule complexes on the infected 
hepatocyte surface may be the primary immune effectors in protective immunity.22 
CD4+ T cells also seem to play a role in recognizing parasite-derived peptide/class II 
MHC molecule complexes.22,23 The mechanism through which CD8+ T cells were 
initially believed to eliminate infected hepatocytes was by direct cytolysis, but more 
recent data revealed that infected hepatocyte elimination is mediated by the release of 
interferon-gamma(IFN-γ) by CD8+ T cells (Fig.3).24 
Individuals living in malaria-endemic regions are constantly exposed to 
Plasmodium infections leading to some naturally acquired immunity; however this 
immunity is slowly developed and only seems to attenuate the severity of the disease 
symptoms. 25 A possible explanation for this could be that the dose of sporozoites 
inoculated is too low to induce and boost immune responses or that suppression of 
anti-sporozoite immunity may occur due to concurrent skin infecting sporozoite stages 
and concurrent blood stage infections.25 
In addition to acquired immunity, there are also some genetic factors that can 
offer some degree of protection against malaria, although through completely different 
mechanisms. Sickle cell trait and other haemoglobinopathies are examples of genetic 
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traits that protect against malaria26; or in the case of P. vivax malaria, as previously 
mentioned, individuals that lack erythrocyte Duffy receptors are also protected against 
blood-stage infection. 
 
 
 
 
 
 
 
 
 
1.6.3 Malaria pre-erythrocytic vaccines 
Pre-erythrocytic vaccines can belong to one of 2 groups: subunit vaccines and 
whole-organism vaccines. 
 
Figure 3 - Proposed mechanism of protective immunity directed against the Plasmodium 
infected hepatocyte.[Image adapted from [22]] - Within the infected hepatocyte, cytoplasmic 
malaria proteins are transformed into short peptides through a proteolytic process by 
proteosomes. These peptides are imported into the endoplasmatic reticulum (ER) via 
transporters associated with antigen processing, TAP1 and TAP2. At the ER, peptides are 
associated with MHC class I molecules and pass through the Golgi apparatus to the cell 
surface. When on the surface, the peptide/MHC complex is recognized by antigen-specific 
CD8+ T cells, the primary immune effectors in malaria protective immunity. Upon activation, 
CD8+ T cells will produce IFN- γ which may be upregulated by a positive feedback loop 
involving dendritic cells, macrophages, NK cells or CD4+ T cells. IFN- γ will then activate nitric 
oxide synthase (iNOS), via signal transducers associated with transcription (STAT), inducing 
the Larginine dependent nitric oxide pathway to eliminate the hepatocyte/intrahepatic 
schizonts.22 
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Subunit vaccines 
Subunit vaccines consist of delivering a specific parasite antigen (without 
introducing any organism) to the vaccinee in order to elicit immune protection against 
the parasite. This type of vaccine‟s major handicap is their lack of immunogenicity, and 
therefore, they often require the use of immunostimulating adjuvants or other similar 
strategies to elicit strong immune response against that specific antigen. RTS,S, the 
most well-known and advanced vaccine candidate against P. falciparum malaria to 
date is an example of this; consisting of a central repeat (NANP) of the 
circumsporozoite (CS) protein of the parasite (R), fused to a region know to contain T 
cell epitopes (T), fused in turn to the hepatitis B surface antigen as a carrier matrix (S), 
self-assembled with unfused S antigen („S)(Fig.4).27 This subunit particle is 
administered in combination with a potent adjuvant (AS01B) that contains the 
immunostimulants, toll-like receptor 4 agonist, and QS21.28 RTS,S has advanced to 
Phase III testing and the results showed a 55% reduction on clinical malaria‟s 
acquisition and a 35% reduction on progression to severe malaria episodes.29 A study 
performed on volunteers, immunized with RTS,S, showed that 6 months post-
immunization, none of the vaccinees was protected. The vaccine induced both 
antibody and CD4+ T cell responses, but CD8+ T cell responses were not 
detectable.30,31 Despite the modest results from RTS,S Phase III trials, there are 
ongoing studies to find a stronger antigen-adjuvant combination. 
 
 
 
 
Figure 4 – Schematic representation of the RTS,S particle. [Image 
adapted from [27]] 
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Whole-organism vaccines 
Whole-organism vaccines consist of administering an attenuated organism in 
order to elicit immune protection against the same organism or a very close related 
organism. In this case, the parasitic form used on whole organism vaccine strategies is 
the sporozoite. 
However, as previously mentioned, it has been shown that dead Plasmodium 
sporozoites fail to induce protection; which can be explained mostly because the 
parasite needs to invade the liver cells in order to elicit differential protection and CD8+ 
T cell responsiveness, in addition to this, it was also shown that the later the liver-stage 
arrest of the parasites, the more efficacious is the protection elicited.32 
Radiation-attenuated sporozoites 
The whole idea of using radiation-attenuated sporozoites (RAS) as a 
vaccination strategy originated on the previously mentioned work of Ruth 
Nussensweig‟s group, showing that immunization of mice with X-irradiated P. berghei 
sporozoites successfully elicits protective immunity.20 In this first approach, sporozoites 
were subjected to a radiation dose between 8.000 and 10.000 rads and 75.000 
sporozoites were injected per mouse. Control and immunized mice were then 
challenged with 1.000 sporozoites per mouse and, strikingly, only 37% of the 
immunized mice developed patent parasitemia as compared with 90% of the controls.20 
Given these encouraging results, in the following years, immunization studies with 
human volunteers, showed that sterile immunity against P. falciparum and P. vivax was 
possible with RAS administered by infected mosquito bites, although in order to be 
effective it would require hundreds of mosquito bites to deliver enough sporozoites to 
elicit protection, therefore it was for many years considered impractical as a vaccination 
strategy.33 More recent studies aimed to compare the efficacy of two administration 
routes for aseptic purified RAS in human volunteers; subcutaneously and 
intradermally.34 The immunization protocol, varied in terms on immunization dose 
(7.500, 30.000 or 135.000 sporozoites per immunization) and number of immunizations 
(4 and 6). When challenged, 3 weeks after last immunization, not only all the immune 
response levels were low but merely 2 of the 80 immunized volunteers developed 
immune protection; 1 immunized 4 times intradermally with 30.000 sporozoites and 1 
immunized 4 times subcutaneously with 30.000 sporozoites.34 Later, another study was 
performed using the same formulation of aseptic purified RAS in humans injected 
intravenously.35 A similar experimental setup to the previous study was performed 
(same immunization doses administered in 4 or 5 immunizations). The results showed 
that the 6/9 volunteers who received 135.000 sporozoites on the 4-dose group and all 
of the 6 volunteers who received 135.000 sporozoites on the 5-dose group were 
protected and did not develop parasitemia while groups that received lower doses were 
not significantly protected.35 This led to the conclusion that not only the administration 
route seems to be of most importance for eliciting protection, but also the number of 
sporozoites used as well as the number of doses received by each volunteer.34,35 
Another concern is that this vaccine candidate uses whole P. falciparum sporozoites as 
the immunogen, leading to possible breakthrough infections to the vaccinees. Based 
on the human trials, it is believed that sporozoite exposure to 15.000-20.000 rads is 
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optimal, as no breakthrough infections were observed and still elicited immune 
protection, although, this approach still represents a risk, as it would require only one 
sporozoite to escape attenuation in order to cause disease.33,36 
Genetically-attenuated sporozoites (GAP) 
With the advancements in the genetic engineering field, the increased 
knowledge of the Plasmodium genome and the possibility of its manipulation, it was 
demonstrated that sporozoites lacking certain stage-specific genes become impaired to 
complete their development inside hepatocytes and confer protective immunity. 37 
Studies with rodent malaria parasites, P. berghei and P. yoelii, showed that these 
parasites could be attenuated by deleting pre-erythrocytic stage-specific genes, such 
as UIS3 and UIS4, and confer sterile protection against wild type parasites.38 These 
genes are involved in the formation of the parasitophorous vacuole membrane during 
the hepatocyte invasion; therefore, their deletion completely arrests parasite 
development during the pre-erythrocytic stage.37 However, unlike in the case of uis3- 
parasites, the use of uis4- parasites led to occasional breakthrough infections, raising 
concerns about the complete attenuation of these parasites.39,40 Other examples 
include the p52-/p36- P. berghei mutants which also showed an early arrest on liver 
stage development, while inducing protective immunity against wild type parasites.41 
However, further studies showed that these parasites are not effectively attenuated and 
that breakthrough infections may occur depending on the mice strain used.42 The only 
GAPs clinical trial performed so far used p52-/p36- attenuated P. falciparum 
sporozoites as a vaccine candidate.43 The immunization protocol consisted on the 
administration of sporozoites by the bite of infected mosquitoes (5 bites on the first 
immunization and 200 on the second). After the second immunization, 1 out 6 
volunteers developed parasitemia after being immunized with 263 bites of infected 
mosquitoes. This event triggered a stopping rule for the clinical trial that led to its 
abortion.43 A PCR was performed and confirmed that the parasites present on the 
volunteer‟s blood were indeed p52-/p35- parasites, showing that even with a successful 
deletion of these genes, rare events may occur whereas the attenuated parasites can 
still progress to blood stage and cause disease.43 Considering all the available GAS 
vaccine candidates, effective attenuation is still a limitation and therefore none has 
successfully undergone phase I trials yet. 
Live-parasite immunization under antimalarial therapy 
This type of vaccine is based on the administration of a drug-susceptible, non-
attenuated parasite along with the drug itself, to elicit immunization without 
development of disease. This approach has proven successful in mice with 
administration of azithromycin with concomitant transmission of P. berghei, eliciting 
protection against further challenges.44 The same kind of study was performed on 
human volunteers with administration of P. falciparum (NF54 chloroquine-sensitive 
strain) and chloroquine, achieving similar long-term immune protection. Subjects were 
exposed to 12-15 infected mosquito bites once a month for 3 months while taking 
chloroquine.45 Individuals were then challenged 2 months after last immunization and 
none of them developed parasitemia, another challenge was performed 28 months 
after the first challenge and only 2 out of 6 individuals developed (delayed) 
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parasitemia.45 Although this vaccination strategy has shown to be efficacious, it is 
difficult to be implemented in the field, given the long immunization protocol and the 
fact that it relies on the administration of live, infectious, non-attenuated P. falciparum 
sporozoites.45 Nonetheless, it encourages further studies regarding the development of 
more whole-organism malaria vaccines. 
Rodent Plasmodium parasites as a vaccination strategy 
Given all the limitations presented by the existing whole-organism, pre-
erythrocytic vaccine candidates, either in terms of safety (use of P. falciparum as 
immunogen), or efficacy, the Prudêncio Lab of the Instituto de Medicina Molecular 
(IMM) has been working on the development of a new whole-organism vaccine using 
fully infectious, genetically modified, P. berghei parasites as a platform for the delivery 
of the immunogenic antigens of human-infective Plasmodium species. 
This new vaccination strategy allows the administration of non-attenuated P. 
berghei sporozoites expressing a protein that is known to be immunodominant in 
human-infective Plasmodium parasites. When comparing the RAS vaccine strategy 
with live-parasite immunization under antimalarial therapy in terms of immunization 
dose required to elicit protection, we can easily understand that in some cases 
attenuated parasites may constitute a suboptimal immunogen as they require a much 
higher immunization dose in order to be effective.43 Therefore, when using non-
attenuated P. berghei sporozoites expressing P. falciparum or P. vivax 
immunodominant proteins we expect to unfold a higher antigenic potential than RAS 
without causing a blood stage infection. 
To validate this new strategy as a potential vaccine candidate against malaria, 
the initial project consisted of(I) evaluating if rodent P. berghei can infect and develop 
in human hepatocytes, therefore following a natural route of infection needed for a pre-
erythrocytic vaccine; (II) showing that P. berghei parasites are unable to cause human 
pathology, thereby ensuring a high safety level. (III) Determining whether a genetically 
modified P. berghei expressing a highly immunogenic human infective Plasmodium 
antigen is able to elicit an immune response able to recognize and inhibit a subsequent 
infection with a similar human parasites. 
In order to assess if P. berghei could or not infect human hepatocytes, several 
in vitro, in vivo and ex vivo experiments were performed. In vitro infection assessment 
was performed using 2 hepatoma cell lines (HepG2 and Huh7) and one immortalized 
hepatocyte cell line (HC-04). Ex vivo infection was performed using primary 
hepatocyte/fibroblast co-cultures. Lastly, In vivo infection was assessed in liver-
humanized mice with wild-type (WT) P. berghei sporozoites. Results showed that P. 
berghei is able to infect human hepatocytes and therefore is a valid option to deliver 
immunizing antigens to human liver cells, where the immunization process is initiated. 
 P. berghei is the most commonly used laboratory model of malaria and is not 
known to cause disease in humans. Nonetheless, in order to demonstrate that P. 
berghei cannot complete its development and multiply inside red blood cells, blood-
humanized mice (engrafted with human erythrocytes) were infected with this parasite. 
Results showed that P. berghei has a very low ability to infect human erythrocytes and, 
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most relevantly, the few merozoites that are able to infect these cells, are unable to 
multiply and cause disease. 
 In order to establish the proof-of-principle of the proposed immunization 
strategy, a highly immunogenic antigen expressed by Plasmodium parasites during 
sporogonic and intrahepatic stages of infection was selected; the circumsporozoite 
(CS) protein. 
The CS protein is a major surface multifunctional protein, expressed on 
sporozoites and early liver stage forms.46 It is believed to be required for the 
hepatocyte invasion process through interaction with heparin sulphate proteoglycans 
(HSPGs) but also appears to be extremely important in the invasion of mosquito‟s 
salivary glands by sporozoites and their exit from mature oocysts.46 The structure of the 
CS protein is highly conserved among Plasmodium species infecting rodents, primates, 
and humans.47 It consists of a central repeat region that varies greatly in repeat 
sequence and repeat number throughout Plasmodium species, flanked by 2 highly 
conserved domains; Region I at the N-terminus and a thrombospondin repeat (TSR) 
motif at the C-terminus, region II.48 A model has been suggested where CS protein 
seems to have 2 conformational states at the sporozoite‟s surface; an adhesive state 
where the TSR motif is exposed, which is displayed during development inside oocysts 
and hepatocyte invasion, and a non-adhesive state where the TSR motif is masked by 
the N-terminus, displayed by sporozoites during salivary gland invasion and migration 
to the liver.46 Previous studies have shown that the CS protein is the immunodominant 
protein of the humoral response to Plasmodium infections.49 CS protein‟s non-
conserved repeat region varies in terms of repeat sequences and number of repeats 
for different Plasmodium species but there is also some variation within the same 
species.50–52 P. vivax CS protein for instance, exists in 3 variations of the predominant 
central repeat sequences; VK210 (GDRA(A/D)GQPA), VK247 (ANGA(G/D)(N/D)QPG) 
and P. vivax-like (APGANQ(E/G)GGAA). 52 
The first approach to the proposed P. berghei-based vaccination strategy 
employed an already existing transgenic P. berghei line, which had its endogenous CS 
protein replaced by P. falciparum‟s CS protein (Pb(PfCS)).48 Results revealed that the 
parasite had relatively low mosquito salivary gland, in vitro, ex vivo and in vivo 
infectivity. A justification for this observation is that the endogenous CS protein might 
be necessary for infection of both mosquito salivary glands and host hepatocytes.48,53 
In light of this, a new transgenic parasite was generated, a P. berghei line expressing 
P. falciparum CS protein under the control of the P. berghei UIS4 promoter 
(Pb(PfCS@UIS4)). This latter approach differs from the previous Pb(PfCS) as the 
PfCS@UIS4 genomic cassette was inserted on an inert genomic locus (230p) rather 
than replacing PbCS with PfCS, allowing both CS proteins (Pb and Pf) to be 
expressed. UIS4 is known to be expressed by sporozoite and liver stages; therefore it 
was expected to lead to the expression of PfCS during those same stages. Also, the 
results showed that salivary gland and hepatocyte infectivity are similar for wild-type 
(WT) and Pb(PfCS@UIS4) parasites, overcoming the initial limitations of the Pb(PfCS) 
parasite. Post-immunization results revealed that sera from Pb(PfCS) and 
Pb(Pf@UIS4) immunized mice; contains high titers of PfCS specific antibodies, are 
able to elicit a cellular immune response; and those antibodies are also able to 
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recognize and bind with high avidity to P. falciparum sporozoites. Additionally there is 
some evidence that there is some cross-species protection between P. berghei and P. 
falciparum conserved epitopes, at the cellular immunity level.54 
The results available so far indicate that this approach can potentially be more 
versatile, efficient and safer than other malaria vaccination strategies. 
Recently, Inês Albuquerque from IMM‟s Prudêncio Lab, using a blood sample 
obtained from a P. vivax-infected patient in the field (Thailand), was able to isolate the 
gene encoding the P. vivax CS protein and insert it on a plasmid containing the 230p 
targeting region and the promoting regions of the UIS4. In order to generate a new P. 
berghei line expressing the P. vivax CS protein, Pb(PvCS@UIS4), a transfection was 
performed according to the GIMO (Gene Insertion Marker Out) method 55, similarly to 
what was done in order to generate the Pb(PfCS@UIS4) transgenic parasite (Fig.5). 
 
 
 
 
 
 
  
The GIMO transfection method consists of using a genetically modified P. 
berghei or P. yoelii as recipient motherline for transfection. These transgenic parasites 
have a positive/negative selection marker (hdhfr::yfcu) stably integrated into the silent 
230p locus. Using a linearized plasmid with a gene of interest fused to the 230p 
targeting region (Fig.5.A), is possible to transfect the recipient motherline by double 
cross-over homologous recombination leading to simultaneous replacement of the 
Figure 5 – Schematic representation of Pb(PvCS@UIS4) transfection 
through GIMO’s transfection method – A – Linearized plasmid containing 
the PvCS@UIS4 gene cassette inside the 230p targeting regions. B – By 
double cross-over homologous recombination, PbGIMO parasites‟ 
positive/negative selectable marker (hdhfr::yfcu) is replaced by the 
PvCS@UIS4 cassette. C – Transfected parasites are negatively selected using 
the 5-FC drug, which will eliminate all parasites that still have the selectable 
marker on their genome, leading to populations where all parasites are 
Pb(PvCS@UIS4). 
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selection marker with the gene of interest (Fig.5.B). After this, the parasites are 
negatively selected with 5-fluorocytosine (5-FC). The 5-FC drug will eliminate any 
parasite that still has the yfcu selectable marker, resulting on the generation of 
parasites with the integrated gene of interest and no drug resistance gene (Fig.5.C).55  
Based on the results obtained with Pb(PfCS@UIS4) parasites, this new 
vaccination strategy represents a good alternative to the ones that have and are being 
developed so far. However the newly generated transgenic parasite, P. berghei 
expressing P. vivax CS under the control of the PbUIS4 promoter (Pb(PvCS@UIS4)), 
requires developmental characterization in order to proceed to more advanced 
immunological studies. After the parasite‟s transfection, 2 clones of Pb(PvCS@UIS4) 
were selected for characterization; Pb(PvCS@UIS4) clone 2 and Pb(PvCS@UIS4) 
clone 4. 
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2. Aims 
As mentioned before, in order to proceed with further, immunological studies, 
the vaccine candidate Pb(PvCS@UIS4), must be fully characterized in terms of 
infectivity and development. . In the specific context of this vaccine candidate, it is also 
important to characterize the expression of the inserted CS gene, to ensure that it is 
being expressed correctly throughout various development stages. Therefore, in order 
to characterize the new vaccine candidate Pb(PvCS@UIS4), the following aims were 
established for this thesis: 
- To compare the PvCS gene sequence from the P. vivax isolate used in this 
study with sequences of the same gene found in isolates from different 
geographic regions across the world. This will ensure that the CS protein 
being inserted into our vaccine candidate is not significantly different from 
the CS protein found in most P. vivax populations worldwide. To do this we 
shall perform a sequence alignment between our PvCS sequence against 
reference sequences found on a Plasmodium genome database 
(PlasmoDB). 
- To characterize Pb(PvCS@UIS4) parasite development and infectivity 
during sporogonic development. This task is to be performed by registering 
oocyst numbers in the mosquito midgut at 10 days post infectious blood 
meal and sporozoites in the mosquito salivary glands at 21 days post 
infectious blood meal. 
- To assess Pb(PvCS@UIS4) parasite‟s ability to infect and develop 
hepatocytes in vitro. In order to do this, two different hepatoma cell lines, 
Huh7 and HepG2, will be infected with freshly isolated sporozoites. Infection 
and development will be assessed by immunofluorescence microscopy at 
48h post infection. 
- To assess the ability of Pb(PvCS@UIS4) parasites to infect and develop in 
vivo. C57BL/6J mice will be infected through i.v. injection of sporozoites. 
Infected livers will be analyzed by qRT-PCR and immunofluorescence 
microscopy. 
- To observe CS protein expression on sporozoites and exo-erythrocytic 
parasite forms, in vitro and in vivo. This will be done by immunofluorescence 
microscopy, using specific antibodies against PbCS and PvCS. 
- Blood-stage development of Pb(PvCS@UIS4) will be analyzed throughout 
time to assess the parasite‟s ability to exit the liver, infect and replicate 
inside erythrocytes. 
Throughout the whole study, Pb(PvCS@UIS4) results will be compared to 
PbGIMO parasites as the latter represent the non-transfected, wild-type parasites. 
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3. Materials and Methods 
 
3.1 Mice (C56BL/6J AND BALB/C) 
In vivo experiments were performed on C56BL/6J and BALB/C mice, ordered 
from Charles River Laboratories international. Ages ranged between 4-6 weeks and 
were housed, upon arrival, in specific pathogen-free conditions, at the animal house 
facility of Instituto de Medicina Molecular (IMM). All the experimental work involving 
animals was performed according to the EU regulations and was approved by the 
Animal Care and Ethical Committees of IMM. 
3.2 Parasite lines 
-Plasmodium berghei GIMO (Gene Insetion Marker Out) 
In order to produce our transgenic parasites, PbGIMO was used as transfection 
motherline, and therefore used as control on characterization experiments. PbGIMO 
has a positive/negative selection marker cassette (hdhfr::yfcu) on the 230p locus. 
 -Plasmodium berghei expressing the Plasmodium vivax CS protein under the 
control of the PbUIS4 promoter (Pb(PvCS@UIS4)) 
This transgenic parasite was produced through the GIMO transfection method 
(by Inês Albuquerque). It expresses P. vivax‟s CS protein under the control of the P. 
berghei UIS4 promoter. Confirmation of integration will be shown in the results section 
of this thesis. After confirmation, 2 clones were selected to proceed with 
characterization; Pb(PvCS@UIS4) Clone 2 and Pb(PvCS@UIS4) Clone 4.  
3.3 Rearing of Anopheles stephensi mosquitoes 
Anopheles stephensi mosquitoes were reared in IMM‟s insectary at 27ºC and 
80% humidity. Larvae developed in trays with water and standard fish food while adult 
mosquitoes were maintained on a 10% sucrose solution with 0,05% of p-aminobenzoic 
acid (PABA), on a 12h light/dark cycle, according to standard rearing conditions.56 The 
rearing schedule is described below (Figure 6);  
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3.4 Maintenance of Plasmodium berghei infections 
Sporozoite collection 
Sporozoites were freshly extracted from the salivary glands of female Anopheles 
stephensi mosquitoes by hand-dissection and collected in RPMI medium. To obtain 
free sporozoites the salivary gland suspension was mechanically homogenized and 
filtered through a 70 μm strainer. Sporozoites were counted in a Neubauer-chamber. 
Figure 6 – Mosquito rearing and infection Schedule – Day 0 corresponds to the day 
that mosquitoes were fed with an infectious blood meal. (Schedule was repeated on a 
weekly basis) Adult female mosquitoes were fed with rodent blood in order to produce 
eggs (16 days before the infectious blood meal). Through the 2 days after feeding, female 
mosquitoes laid their eggs. Eggs hatched and larvae emerged (-16 to -14). Larvae grew in 
size through the following 7-8 days (-14 to -6). At day -6, larvae began to pupate. Also, on 
the same day, mice were injected i.p. with an vial of frozen parasite stabilates. At day -3, 
mosquitoes started to emerge from pupae. Mouse parasitemias were checked daily until 
4% parasitemia. Male gametocyte exflagellation was accessed as it is a strong indicator of 
transmission capacity of infected mice. At the day previous to blood infection, adult 
mosquitoes were moved from the insectary to a mosquito incubator and left on starvation 
for 24h. The following day (day 0), infected mice were anesthetized and used to feed 
starved mosquitoes. Within the mosquito, ookinets are formed and develop into oocysts on 
the first 3 days post infectious blood meal. From day 3 to 18, oocysts grow in size. At day 
18, oocysts start to burst and release sporozoites, which migrate to the salivary glands 
through the following 3 days. At day 21, sporozoites are already on the salivary glands and 
ready for dissection. 
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Monitoring of parasitemias 
A small incision was made on the tip of the mouse tail and a small drop of blood 
was placed on a glass slide. The blood was smeared by using a second glass slide, 
dried in air, fixed in methanol for 30 seconds and stained in Giemsa solution for 10 min. 
The smear was dried in air and observed with a x100 oil immersion objective. 
Exflagellation test 
Similarly to what is done for monitoring parasitemias, a drop of blood is collected to 
a microscope slide and a coverslip is placed on top of it and left at room temperature 
for 7 min. The slide was observed on an optical microscope with phase or interference 
contrast with a ×40 objective. Exflagellation is noted by the violent lashing movements 
of the male gamete flagella. 
Oocyst counts 
For oocyst counts, mosquito midguts were hand-dissected 10 days after the 
infectious blood meal. To enhance contrast, midguts were mounted on a glass slide 
with a drop of mercurochrome. Oocysts were then counted using an Olympus CX41 
optical microscope with a 20x objective. 
Mouse infection 
BALB/C mice were infected through intraperitoneal injection with 106 parasited red 
blood cells, from either PbGIMO or Pb(PvCS@UIS4) clone 2/4, collected from a 
previously infected mouse (direct blood transfer) or from a stored frozen parasite 
stabilate. Normally, “mouse-to-mouse” blood transfers never exceed 5 passages (due 
to telomeric erosion of the parasite), after which a blood vial is injected instead. 
Mosquito infection 
Infected mouse parasitemias were counted 3-4 days after passage. When 
parasitemias range between 4%-20% and the exflagellation test shows more than 2 
exflagellation events per field it means that the gametocytes present on the blood are 
potentially infectious to the mosquitoes. Before the blood meal, the mouse was 
anesthetized (ketamine-xylazine) and placed on the top of a cage with previously 
starved female mosquitoes. The mouse remained on top of the cage (belly down) for at 
least 30min, so most of the mosquitoes present on the cages had enough time to bite. 
During the blood meal, the cage was maintained at 19ºC-21ºC on a darkened 
environment. After the feeding, mosquitoes were left in incubators at 21ºC and 80% 
humidity and 12h light/dark cycle until sporozoite collection. 
3.5 In vitro culture of hepato-cellular carcinoma celllines 
For in vitro characterization of Pb(PvCS@UIS4) parasites, cultures of 2  human 
adherent hepatoma  cell lines, Huh7 and HepG2, were employed. 
Huh7 cells were cultured in RPMI 1640 medium supplemented with 10% fetal 
calf serum (FCS),1% non-essential amino acids, 1% penicillin/streptomycin,1% 
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glutamine and 10mM 4-(2-hydroxyethyl)-1-piperazine ethanesulphonic acid (HEPES), 
pH 7, and maintained at 37ºC with 5% CO2.  
HepG2 were cultured in DMEM medium supplemented with 10% fetal calf 
serum (FCS), 1% non-essential amino acids, 1% penicillin/streptomycin, 1% glutamine 
and 10 mM 4-(2-hydroxyethyl)-1-piperazineethane-sulphonic acid (HEPES), pH 7, and 
maintained at 37 ºC with 5%CO2. 
3.6 In vitro infection 
In order to analyze infection, cells were seeded 1 day before infection, on 24-
well plates (with coverslips), with a confluence of 50.000 cells/well for Huh7 and 70.000 
cells/well for HepG2. On the day of infection, each well was infected with 30.000 
sporozoites obtained from infected mosquito‟s salivary glands (21-29 days after 
infectious blood meal), plates were then centrifuged (3000 RPMs for 5 min) and 
incubated at 37ºC for 48h. At 48h post-infection, cells were fixed with 
paraformaldehyde (4%) for 10 min, washed with 1x PBS and stored at 4ºC. 
3.7 In vivo experiments 
C56BL/6J mice were anesthetized with isofluorane and then inoculated by retro 
orbital injection with sporozoites obtained from infected mosquitoes (21 days after the 
infectious blood meal). Each mouse was injected with 30.000 sporozoites. At 44h post 
inoculation, all mice were sacrificed and their livers collected. The left liver lobes were 
snap-frozen in liquid nitrogen and stored at -80ºC (to be used for qRT-PCR analysis); 
the remaining was fixed on 4% paraformaldehyde and stored at 4ºc (for microscopy). 
3.8 RNA extraction and cDNA synthesis 
With a blender rod, mouse livers were homogenized in denaturing solution (4M 
guanidinium thiocyanate, 25mM sodium citrate, pH 7.0, 0.5% n-lauryl sacosomine) 
supplemented with 0.1M β-mercaptoethanol. After homogenization, RNA was extracted 
using a Quiagen RNA extraction kit (volume of elution, 35μl). 
RNA was quantified on a NanoDrop 1000 Spectrophotometer and dilutions 
were made so that all samples were at final RNA concentration 200 μg/μl. One μg (5μl) 
of each sample‟s RNA was used to synthesize cDNA according to the following 
reaction: 
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cDNA reaction mixture Volume μL/reaction 
10x Buffer 2 
 50µg/mL Random Hexamer  1 
10mM dNTP mix 1 
40 U/μL RNAse inhibitor 0,5 
200 U/μL Reverse transcriptase 1 
H2O 9,5 
Template RNA (1μg) 5 
Final Volume 20 
 
 
cDNA synthesis program was as follows:  25ºC – 10 min; 55ºC – 30 min; 85ºC – 5 min. 
Reaction performed on a Biometra Personal Thermo cycler. 
3.9 Real Time quantitave PCR 
Malaria infection was quantified using quantitative real-time PCR with primers 
specific for P. berghei 18S and normalized to an endogenous mouse housekeeping 
gene, HPRT (Hypoxanthine Guanine Phosphoribosyl Transferase). The primers were 
designed to span exon-exon junctions, to avoid genomic DNA amplification, and so, 
RNA-DNAse treatment was not required. Two μl of cDNA from each sample were 
added per well on a 96-well PCR-plate (2 wells per sample) along with the qRT-PCR 
Mixture (see table below).  
18S RT-PCR Mixture 
Volume 
μL/reaction 
HPRT RT-PCR Mixture 
Volume 
μL/reaction 
SYBR® Green Real-Time 
PCR Master Mix 
 
10 SYBR® Green Real-Time 
PCR Master Mix 
 
10 
18S Forward primer 0,4 HPRT Forward primer 0,4 
18S Reverse primer 0,4 HPRT Reverse primer 0,4 
H2O 7,2 H2O 7,2 
cDNA Template 2 cDNA Template 2 
 
 
Table 2 – qRT-PCR 
mixture components 
 
Table 1 – cDNA 
reaction mixture 
components 
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To analyze infection, gene expression was analyzed by the comparative CT 
(cycle threshold) method and a ratio between 18S and HPRT was calculated for each 
sample; 2HPRT/218S and compared between samples. 
 
3.10 Genomic DNA extraction from blood stage parasites 
Parasite DNA used in the PCR for confirmation of transgenic integration was 
extracted from infected whole-blood vials by the phenol-chloroform method. The blood 
sample was centrifuged at 13.000 RPM for 1 min in order to create a cell pellet. 
Supernatant was discarded and added 350μl of RBC lysis buffer to the cell pellet. The 
pellets were resuspended and vortexed in order to lyse the cells efficaciously. The 
sample was transferred to a new tube and added 10μL of RNaseA (10mg/mL) and 
incubated for 10min at 37ºC. After incubation, 10μL of proteinase K (20mg/mL) were 
added to the tube and incubated for 1h at 37ºC. Phenol was added to a final volume of 
750 μl. Tube was inverted several times and centrifuged at maximum speed for 5 min. 
The supernatant was transferred to a clean tube. Phenol/chloroform/isoamylalcohol 
(25:24:1) was added up to 1,5 ml. The tube was inverted several times and centrifuged 
at 13.000 for 5 min. The supernatant was again transferred into a clean tube and 
chloroform/isoamylalcohol (24:1) was added up to 1,5 ml. Tube was inverted several 
times and centrifuged at 13.000 for 5 min. The supernatant was transferred into a new 
tube and added 1/10 volume of 3M Sodium Acetate and 96% ethanol for precipitation. 
The tube was then centrifuged 13.000 speed for 10min. Supernatant was discarded 
and the pellet was washed with 70% ethanol, air-dried and dissolved in MiliQ water. 
DNA was then quantified on a Nanodrop 2000. 
3.11 Confirmation PCR for genomic integration 
 In order to confirm that the transfection occurred as expected and that the 
PvCS@UIS4 cassette was successfully inserted in the 230p genomic locus of the 
Table 3 – qRT-PCR 
reaction program 
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parasite, 3 different PCR reactions were performed; 5‟ integration, 3‟ integration and 
selectable marker (see results for details). 
PCR Reaction Mixture Volume μL/reaction 
10x PCR buffer 5 
50mM MgCl2 3 
NZYTaq DNA polimerase 0,5 
0.1M dNTP 1,25 
DNA template 50ng 
Forward primer 2,5 
Reverse primer 2,5 
H2O until 50μL of total volume 
 
 
 
 
 
 
After the reaction, PCR products were run on a 1% agarose gel and revealed 
on a Chemidoc XRS+. 
3.12 Antibody production and acquisition 
In order to produce antibodies against PvCS and PbCS, 2 hydridoma cell lines, 
2F2 and 3D11 respectively, were ordered from MR4 (Malaria Research and Reference 
Reagent Resource Center) and cultured in the lab:  
Cells were thawed at 37ºC and ressuspended in 5 mL of DMEM medium. After 
cell resuspension, these were transfered on to a culture flask with 15 mL of fresh 
DMEM medium supplemented with 10-15% FBS and left in the incubator at 37ºC. 
Table 5 – 5’ and 3’ 
confirmation of integration 
PCR reaction program 
 
Table 6 – Selectable marker 
confirmation of integration 
PCR reaction program 
 
Table 4 – PCR reaction 
mixture components 
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Every two days, the cells were aspirated from the culture flask and centrifuged at 1800 
RPM for 5 min. After centrifugation, the supernatant containing the antibodies were 
collected and stored at 4ºC. Cells were then resuspended and based on the confluence 
were split into 2 or 3 culture flasks with fresh DMEM medium. This process was 
repeated until obtaining 2L of antibody-containing supernatant. Cells in the supernatant 
were removed by centrifugation at 10000 RPMs for 20 min. In order to precipitate the 
antibodies present in the supernatant, a 2L saturated solution of ammonium sulfate 
were previously prepared (900g per 1L of H2O). Ammonium sulfate was slowly added 
to the supernatant and left overnight with constant stirring. On the following day, the 
solution was transferred to 250mL flasks and centrifuged at 10.000 RPM for 20min 
(4ºC). The supernatant was discarded and the pellet was resuspended in PBS. This 
solution was then transferred to a dialysis membrane and dialyzed against PBS. The 
solution was finally stored at -80ºC and sent to Dr. Ricardo Franco‟s laboratory (FCT-
UNL) where the final steps of the purification were performed. 
3.13 Imunofluorescence microscopy 
Sporozoites 
Following sporozoite collection, 30.000 sporozoites /well were placed on a “10-
well slide” (ThermoScientific Diagnosis Microscope slides) and left at room temperature 
until the wells were completely dry. After drying, sporozoites were fixed with 4% 
paraformaldehyde for 10min and then washed with PBS. The CS protein is found at the 
parasite‟s membrane, so no permeabilization was required. Sporozoites were then 
incubated with 3D11 (against P. berghei CS) and 2F2 (against P. vivax CS). Both 
antibodies were obtained from mouse hybridomas, therefore the staining had to be 
done in 2 different wells for each parasite. Both antibodies were diluted on PBS with 
0,25% gelatin, 1:200 3D11 and 1:500 2F2. Twenty-five μl of each antibody solution 
were used per well. The slides were left inside a wet chamber at 37ºC for 30min. Slides 
were washed with PBS and 25 μl of a secondary antibody solution containing Alexa-
Fluor 488 anti-mouse, Donkey IgG (1:500) and Hoechst(1:150) were placed on each 
well. Slides were left on a wet chamber for 30min at 37ºC. After that, each slide was 
mounted with Fluoromount G (MARCA) and a cover slide. Immunofluorescent CS 
protein localization and expression images were acquired on a Zeiss LSM 710 confocal 
point-scanning microscope with a 63x objective, 1660x1660 resolution, 4 scans, 
scanspeed 6. 
Coverslips 
Coverslips obtained from in vitro culture and infection of hepatoma cell lines 
were fixed with 4% paraformaldehyde for 10 min (as stated above). After that, cells 
were permeabilized with PBS, 0.25% Triton X-100 and 1% Bovine Serum Albumin 
(BSA) for 1h. Primary antibodies used were either 3D11 and a-UIS4 or 2F2 and a-
UIS4. These were diluted on the solution used for permeabilization; 3D11 (1:200), 2F2 
(1:500), UIS4 (1:450). Each coverslip was incubated with a single drop of antibody 
solution in a wet chamber for 1,5h at room temperature. Coverslips were then washed 
and incubated with secondary antibodies; Alexa-Fluor 488 (anti-mouse, Donkey IgG), 
Alexa-Fluor 555 (anti-goat, Donkey IgG) and Hoechst (for nuclei labeling). Coverslips 
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were left in a wet chamber for another 1,5h. Coverslips were then washed thrice and 
mounted with Fluoromount G (Southern Biotech). EEFs were counted on a Zeiss 
Axiovert200MWidefield fluorescence microscope, with a 20x objective, and normalized 
to the total number of nuclei. EEF size was also measured on the same microscope 
with a 40x objective. Immunofluorescent CS protein localization and expression images 
were acquired on a Zeiss LSM 710 confocal point-scanning microscope with a 63x 
ojective. Images acquired with 1750x1750 resolution, 4 scans, scanspeed 6. Images of 
immunofluorescence-stained sections were analyzed with ImageJ 1.49b software. 
Liver slices 
Livers previously collected and fixed in 4% paraformaldehyde for 10 min, were 
washed and then sliced into 50-μm sections using a vibratome (VT1000S, Leica). 
Sections were permeabilized and blocked overnight in 0,5% Triton X-100, 1% Bovine 
Serum Albumin (BSA) and IgG anti-mouse (1:150), washed thrice with PBS, and 
incubated with primary antibodies for 2h; Primary antibodies employed were 
3D11(1:200) and anti-UIS4(1:450) or 2F2(1:500) and anti-UIS4 (liver slices were 
divided into 2 groups for each parasite, in order to perform both stainings). After 
primary antibody incubation, sections were washed thrice with PBS and incubated with 
the following secondary antibodies; Alexa-Fluor 488 1:500(anti-mouse, Donkey IgG), 
Alexa-Fluor 555 1:500(anti-goat, Donkey IgG), Alexa-Fluor 660–phaloidin 1:50 and 
Hoechst 1:150. Sections were mounted on slides with Fluoromount G (Southern 
Biotech).  EEFs were counted on a Zeiss Axiovert200M Widefield fluorescence 
microscope, with a 10x objective, and normalized to the total area observed of the 
slices. EEF size was also measured on the same microscope with a 40x objective. 
Immunofluorescent CS protein localization and expression images were acquired on a 
Zeiss LSM 710 confocal point-scanning microscope using a 63x objective. Images 
were acquired with 1024x1024 resolution, 4 scans, scanspeed 6. Images of 
immunofluorescence-stained sections were analyzed with ImageJ 1.49b software. 
3.14 Statistical analyses 
Results were expressed in terms of mean ± standard error of the mean (SEM). 
Statistical comparisons were made using the Mann-Whitney non-parametric test. 
 
 
 
 
28 
 
4. Results 
 
4.1 Characterization of the PvCS sequence 
Before the transfection of PbGIMO parasites in order to originate 
Pb(PvCS@UIS4) parasites, vector plasmids were generated, containing the PvCS 
gene sequence flanked by the PbUIS4 promoter sequences forming a cassette fused 
to the 230p targeting region. These vector plasmids were amplified by transforming 
competent bacteria and subsequently sequenced (Stabvida sequencing services). 
Consensus of the different sequenced bacterial colonies can be viewed on Appendix 2. 
Using these sequencing results, the PvCS gene selected for parasite transfection was 
aligned against reference PvCS gene sequences present on PlasmoDB (Sal-1, Brazil I 
and India VII), in order to evaluate the divergence of the PvCS gene amplified from our 
P. vivax isolate from Thailand in terms of mutations/polymorphism and central region 
repeat sequence number and diversity. Reference sequences used for alignment 
belong to isolates from Salvador, Brazil and India, respectively (Fig.7).  
 
 
 
 
Figure 7 – Schematic representation of PvCS protein 
SNP alignment blast. Alignment blast was performed 
between the PvCS sequence from our isolate (from 
Thailand) and the Sal-1 (Salvador), Brazil I and India VII 
isolates. N-terminus and C-terminus regions are 
represented in green and orange, respectively. Each 
numeric square represents a central region repeat. Non-
synonymous SNPs are highlighted below. 
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As expected, both the N-terminus and C-terminus regions were extremely 
conserved in relation to the reference PvCS sequences present on PlasmoDB, with a 
single non-synonymous polymorphic event at position 38, originating a transition from 
an asparagine to a glycine. However, a great variability on the central repeat region 
can be observed. 
As previously mentioned, three major variants of the central repeat regions of 
the P. vivax CS have been described; VK210 (GDRA(A/D)GQPA), VK247 
(ANGA(G/D)(N/D)QPG) and a much less common variant named P. vivax-like 
(APGANQ(E/G)GGAA).52 Both VK210 and VK247 variants are globally distributed, but 
some geographic biases have been described on several studies.47,51,52,57 Our results 
indicate that the PvCS sequence used in our study is similar to the most common and 
well adapted variant of the P. vivax CS protein, the VK210. Besides being the most 
widely spread, previous studies revealed that Anopheles mosquitoes appear to be 
more easily infected by the VK210 variant of P. vivax.58 Despite VK210 variant‟s most 
common peptide repeat motifs being GDRADGQPA and GDRAAGQPA, our isolate 
has one other peptide repeat motif; GNGAGGQAA. This central repeat has also been 
found on two other studies performed on Sri Lanka‟s and Brazil‟s P. vivax 
populations.47,51 Insertions and deletions in the central repeat domain generate different 
CS protein variants that may be positively selected if the mutant parasites evade host 
immunity.51 In theory, these variations can affect the structure of the CS protein and 
may be responsible for parasite‟s evasion of natural variant-specific immunity. 
However, there is no proof of whether or not that is the case. 
 
4.2 PCR confirmation of the genomic integration for the PvCS@UIS4 
gene cassette 
After GIMO-transfection, parasite populations consist in a mix between 
transfected and non-transfected parasites despite the negative selection process 
performed with 5-FC; therefore, parasite cloning after negative selection is an essential 
step in GIMO-transfection in order to obtain a clonal population originated from a single 
transfected parasite that express the transgene (with no selectable marker). Parasite 
cloning consists in injecting a dilution of mouse blood infected with a mixed population 
of transfected and non-transfected parasites that is equivalent to approximately a 
single parasite being injected per mouse so that only a clonal population develops from 
a single parasite. In order to ensure that our clonal populations of Pb(PvCS@UIS4) 
(clone 2 and clone 4) parasites consist only of successfully transfected parasites a 
series of PCR reactions were performed (Fig. 8.A/B). First, PCR reaction primers, were 
designed to amplify only in case of proper 5‟ integration; the uma1654 forward primer 
binds outside the 230p targeting region and the uma1494 reverse primer binds inside 
the integrated region at 5‟UIS4 UTR (expected amplicon size – 1240bp). Similarly to 
the first reaction, the second PCR reaction would only amplify if proper 3‟ integration 
occurred; the uma1497 forward primer binds inside the integrated region at 3‟UIS4 
UTR and the uma1655 reverse primer binds outside the 230p locus targeting region 
(expected amplicon size – 1989bp). As mentioned before, upon transfection, the 
selectable marker present in the 230p locus of PbGIMO parasites is replaced by the 
PvCS@UIS4 cassette. In order to ensure that there are no mixed populations, the 
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reaction performed with uma1901 (hdhfr forward primer) and  uma1902 (yfcu reverse 
primer), only amplifies if the parasite contains the selectable marker cassette, thereby 
demonstrating whether or not the Pb(PvCS@UIS4) clones consist in mixed populations 
of transfected and non-transfected (PbGIMO) parasites (no amplification expected for 
Pb(PvCS@UIS4) clones). Our results show that both clones have correct 5‟ and 3‟ 
integration and none of them showed amplification of the selectable marker cassette; 
therefore no untransfected parasites are present on Pb(PvCS@UIS4) clone 2 and 4 
populations (Fig 8.C). See appendix 1 for primer sequences. 
 
 
 
 
 
Figure 8 – A – Schematic representation of the GIMO transfection method used to 
generate Pb(PvCS@UIS4) parasites with integration PCR primer binding sites. B – 
Table with primers and respective reaction amplicons. C- Agarose gel showing 
PCR results that confirmed correct integration and absence of selectable markers 
for both Pb(PvCS@UIS4) clones. 
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4.3 Mosquito stage development of Pb(PvCS@UIS4) parasites 
After demonstrating correct integration of the PvCS@UIS4 cassette into the 
Pb(PvCS@UIS4) parasites genome, mosquito stage characterization experiments 
were performed, to compare the growth kinetics of these parasites with those of the 
PbGIMO (WT) parasite . 
4.3.1 Oocyst Development of Pb(PvCS@UIS4) parasites 
In order to evaluate the ability of Pb(PvCS@UIS4) parasites to infect and 
develop inside the mosquito, oocysts were counted at day 10 post-infected blood meal. 
Oocyst numbers were compared between Pb(PvCS@UIS4) clones 2 & 4 and PbGIMO 
parasites. Results presented on Fig.9.A indicate that Pb(PvCS@UIS4)clones and 
PbGIMO parasites present a similar capacity to invade, adhere and develop inside A. 
stephensi midguts. For each group, 30 midguts were analyzed in total (3 experiments); 
[PbGIMO] 83,3% midguts infected, 172,7 ± 26,19 oocysts; [Pb(PvCS@UIS4) Clone2] 
90% midguts infected, 171,2 ± 22 oocysts; [Pb(PvCS@UIS4) Clone 4] 80% midguts 
infected, 195,8 ± 24,71 oocysts (Fig.9.A). Results are expressed in mean number of 
oocysts per midgut, accompanied by the standard error of the mean. 
These findings suggest that the presence of the PvCS gene on the 
Pb(PvCS@UIS4) transgenic parasites has no effect on the initial development stages 
of the parasite inside the mosquito. 
4.3.2 Sporozoite development and salivary gland infectivity of 
Pb(PvCS@UIS4) parasites 
Mosquitoes used for sporozoite collection were selected 24h after the infected 
blood meal, to ensure all mosquitoes used for this experiment were fed. Twenty to 22 
days after the blood meal, mosquitoes were dissected and sporozoites present on the 
salivary glands were collected. The number of sporozoites inside the mosquito salivary 
glands was recorded for 5 different experimental infections, with 25-35 mosquitoes 
dissected for each group of infected mosquitoes. Results show that both 
Pb(PvCS@UIS4) clones 2/4 and PbGIMO present similar numbers of sporozoites in 
mosquito salivary glands 20-22 days post mosquito infection (Fig 9.B); [PbGIMO] 
48231 ± 5017; [Pb(PvCS@UIS4) Clone 2] 54753 ± 9948; [Pb(PvCS@UIS4) Clone 4] 
55801 ± 6558 (Fig.9.B). Results are expressed as mean number of sporozoites per 
mosquito ± standard error of the mean. These results suggest that the presence of the 
PvCS protein on the transgenic Pb(PvCS@UIS4) parasite, has no effect on its capacity 
to complete oocyst development, form and release sporozoites, and on the ability of 
sporozoites to migrate to and invade salivary glands.  
As previously stated, salivary gland infection was greatly reduced on a previous 
transgenic parasite in which the endogenous PbCS gene was replaced by the CS gene 
of the P. falciparum parasite. An possible explanation for this is that PfCS has reduced 
function within P. berghei background, probably because region II of the CS protein 
(which has been shown to be essential for salivary gland invasion) is slightly different 
between P. berghei and P. falciparum or simply because the replacement of PbCS by 
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PfCS could have altered the sequences around the conserved regions and somehow 
impaired sporozoite motility. Either way, by inserting PvCS in the 230p silent locus, that 
limitation has been successfully overcome. 
 
 
 
 
 
 
4.3.3 PbCS and PvCS expression in Pb(PvCS@UIS4) parasites in 
mosquito stages 
To determine the expression of the PbCS and PvCS proteins on 
Pb(PvCS@UIS4) parasites, immunofluorescence assays were performed on 
sporozoites collected from infected mosquito salivary glands. In order to confirm 
expression and rule out possible cross reactivity from the antibodies, for each group 
(PbGIMO and Pb(PvCS@UIS4) clones 2&4), sporozoites were labeled with either 
3D11 (anti-PbCS) or 2F2 (anti-PvCS) mouse monoclonal primary antibodies and a 
secondary anti-mouse antibody conjugated with a 488 nm fluorochrome. These 
parasites were imaged on a confocal point-scanning microscope using an excitation 
laser (488 nm) as well as the differential interference contrast (DIC) optical microscopy 
illumination technique, to enable visualization of sporozoites regardless of labeling 
(Fig.10). The results show that both Pb(PvCS@UIS4) clones 2 & 4 express both PbCS 
and PvCS (Fig.10.B/C), while PbGIMO sporozoites only exhibit a fluorescent signal for 
PbCS (Fig 10.A), showing that 2F2 antibodies are specific for PvCS and have no cross 
reactivity with PbCS. Expression of PvCS at this stage was expected because in 
Pb(PvCS@UIS4), the PvCS gene is being expressed under the control of the promoter 
regions for thePbUIS4 (a protein expressed from sporozoite stage until late liver stage 
EEFs).39 Also, PbCS expression on both Pb(PvCS@UIS4) clones is similar to the 
expression of PbCS in PbGIMO, which was also expected, as it is essential for the 
parasite to conclude its cycle inside the mosquito efficaciously.48  
Figure 9 - Pb(PvCS@UIS4) Development inside the mosquito compared to 
PbGIMO motherline– A – Number of oocyst per mosquito midgut at day 10 post 
infectious blood meal. B – Number of sporozoites inside mosquito salivary glands 
20-22 days after infectious blood meal. Bars indicate the mean of all observations 
and error bars represent standard error of the mean. Mann-Whitney test was 
applied between Pb(PvCS@UIS4) clones and PbGIMO indicating no significant 
differences between the parasite lines (p>0,05). 
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Figure 10 – Differential interference contrast (DIC) and immunofluorescence 
microscopy imaging of sporozoites – A – PbGIMO sporozoites labeled with 
3D11 (green) for PbCS expression (top row). Labeling with 2F2 (gold) for PvCS 
expression (bottom row). B - Pb(PvCS@UIS4) clone 2 sporozoites labeled with 
3D11(green) for PbCS expression (top row). Labeling with 2F2 (gold) for PvCS 
expression (bottom row). C- Pb(PvCS@UIS4) clone 4 sporozoites labeled with 
3D11(green) for PbCS expression (top row). Labeling with 2F2 (gold) for PvCS 
expression (bottom row). Microsopy settings remained unchanged for all images 
(laser intensity, scan speed, resolution). Scale bar (Cyan blue) = 21 μm 
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4.4 In vitro characterization of Pb(PvCS@UIS4) parasites 
Having characterized the capacity of Pb(PvCS@UIS4) to infect and develop 
within the Anopheles mosquitoes, it was important to characterize the parasite‟s 
capacity to infect and develop inside hepatic cells. To that end, two human hepatoma 
cell lines, Huh7 and HepG2 cells, were used to perform in vitro infectivity assays.  
4.4.1 In vitro infection assays in Huh7 hepatoma cells 
To assess the infectivity and development of Pb(PvCS@UIS4) parasites, three 
independent infections were performed. In each experiment two microscopy coverslips 
were seeded with 50.000 cells and infected with 30.000 sporozoites for each of the 
three parasite groups (PbGIMO, Pb(PvCS@UIS4) clones 2&4). Cells were fixed and 
labeled 48h post infection. Labeling was performed with 2E6 antibodies for PbHSP70 
and Hoechst for nuclei (Fig.11).  
Figure 11 – Infectivity and development of Pb(PvCS@UIS4) in Huh7 cells – A – 
Pb(PvCS@UIS4) clones infectivity in Huh7 cells, 48h post infection, relative to 
control (PbGIMO). B – Parasite development inside Huh7 cells measured as EEF 
area 48h post infection. Results are expressed as means and error bars represent 
standard error of the mean. Mann-Whitney test was applied between 
Pb(PvCS@UIS4) clones and PbGIMO showed no significant difference (p>0,05). C 
– Representative immunofluorescence microscopy pictures of Huh7 cells infected 
with the different parasite lines 48h p.i. EEFs labeled with 2E6 primary antibodies 
(green) and cell nuclei labeled with Hoechst (blue). Scale bar (Cyan blue) = 100 
μm 
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In order to determine infectivity, coverslips were analyzed on an Axiovert 200M 
wide field microscope. Total infectivity was calculated as the ratio between infected and 
non-infected hepatocytes. Infectivity was then normalized to 100% of PbGIMO 
infection, showing no significant statistical difference between Pb(PvCS@UIS4) clones 
and PbGIMO (p>0,05); [PbGIMO] 0,1038% ± 0,01616% ;[Pb(PvCS@UIS4)Clone 2] 
0,8828% ± 0,02447% (85% of control) ;[Pb(PvCS@UIS4) Clone 4] 0,1256% ± 
0,01164% (121% of control) (Fig.11.A). 
Development was assessed through microscopy by measuring the total area of 
approximately 60 EEFs of each parasite; [PbGIMO] 135,1 ± 7,078 μm2; 
[Pb(PvCS@UIS4)Clone 2] 142,6 ± 9,535 μm2; [Pb(PvCS@UIS4) Clone 4] 122,9 ± 
7,921 μm2 (Fig.11.B). These results are expressed as mean area of EEFs ± standard 
error of the mean. 
 
4.4.2 Expression assays in Huh7 hepatoma cells 
Expression assays for PbCS and PvCS have been performed on Huh7 cells, 
48h post infection with PbGIMO or Pb(PvCS@UIS4) clones 2&4 parasites, 
respectively. Coverslips containing infected cells were incubated with either 3D11(anti-
PbCS) + anti-PbUIS4 or 2F2(anti-PvCS) + anti-UIS4 primary antibodies, and 
corresponding secondary antibodies; Alexa-Fluor 488 anti-mouse IgG (for 3D11 and 
2F2), Alexa-Fluor 568 anti-goat IgG (for anti-UIS4) and Hoechst for nuclei labeling. 
PbUIS4 works as a control labeling, as it enables visualizing EEFs regardless of CS 
expression. Images were acquired on a Zeiss LSM710 confocal microscope and all 
settings remained unchanged for each channel. As expected, the results indicate that 
both Pb(PvCS@UIS4) clones express both PvCS and PbCS, while PbGIMO expresses 
only PbCS (Fig.12). 
 
4.4.3 In vitro infection assays in HepG2 hepatoma cells 
Similarly to Huh7 assays, three independent infections were performed with 
HepG2 cells. Each experiment employed two microscopy coverslips seeded with 
70.000 cells and infected with 30.000 sporozoites for each of the three parasite groups 
(PbGIMO, Pb(PvCS@UIS4) clones 2&4). HepG2 cells grow slower than Huh7 cells, 
hence the higher initial number (70000 cells instead of 50000 cells). Cells were fixed 
and labeled 48h post infection. Labeling was performed with 2E6 antibodies (anti-
HSP70) and Hoescht (Fig.13.C). To determine infectivity, coverslips were analyzed on 
an Axiovert200M widefield microscope. Total infectivity was calculated as the ratio 
between EEFs and non-infected hepatocytes, infectivity was then normalized to 100% 
of PbGIMO infection, with no significant differences found between them (p>0,05); 
[PbGIMO] 0,8% ± 0,09416%; [Pb(PvCS@UIS4) clone 2] 0,7691% ± 0,1153 (92,366% 
of control);[Pb(PvCS@UIS4) clone 4] 0,8188% ± 0,1799% (98,337% of control) 
(Fig.13.A). 
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Figure 12 - Immunofluorescence microscopy of exoerythrocytic forms in 
Huh7 cell culture – A- PbGIMO EEFs labeled with 3D11 (green) for PbCS 
expression  and anti-UIS4 (red) (top row). Labeling with 2F2 (gold) for PvCS 
expression (bottom row). B -Pb(PvCS@UIS4) clone 2 EEFs labeled with 3D11 
(green) for PbCS expression  and anti-UIS4 (red) (top row). Labeling with 2F2 
(gold) for PvCS expression (bottom row). C - Pb(PvCS@UIS4) clone 4 EEFs 
labeled with 3D11 (green) for PbCS expression  and anti-UIS4 (red) (top row). 
Labeling with 2F2 (gold) for PvCS expression (bottom row). Cell nuclei labeled 
with Hoechst (blue).All cultures were fixed at 48 hpi. Scale bar (Cyan blue) = 
21 μm 
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Parasite development was assessed through microscopy by measuring the total 
area of about 120 EEFs of each parasite group; [PbGIMO] 269,7 ± 15,27 
μm2;[Pb(PvCS@UIS4) clone 2] 290,8 ± 15,85 μm2;[Pb(PvCS@UIS4) clone 4] 222,8 ± 
12,48 μm2 (Fig.13.B). These results are expressed as mean area of EEFs ± standard 
error of the mean. 
 
 
4.4.4 Expression assays in HepG2 hepatoma cells 
PbCS and PvCS expression on HepG2 cells was determined 48h post infection 
with PbGIMO or Pb(PvCS@UIS4) clones 2&4 parasites, respectively (Fig.14). 
Coverslips containing infected cells were incubated with either 3D11(PbCS) + anti-
PbUIS4 or with 2F2(PvCS) + anti-PbUIS4 primary antibodies, and corresponding 
secondary antibodies; Alexa-Fluor 488 anti-mouse IgG (for 3D11 and 2F2), Alexa-Fluor 
568 anti-goat IgG (for anti-UIS4) and Hoechst for nuclei labeling. Anti-PbUIS4 was 
used as a control labeling. Images were acquired on a Zeiss LSM710 confocal  
Figure 13 – Infectivity and development of Pb(PvCS@UIS4) in HepG2 cells – A 
– Pb(PvCS@UIS4) clones infectivity in HepG2 cells, 48h post infection, relative to 
control (PbGIMO). B – Parasite development inside HepG2 cells measured as EEF 
size 48h post infection. Results are expressed as means and error bars represent 
standard error of the mean. Mann-Whitney test was applied between 
Pb(PvCS@UIS4) clones and PbGIMO showed no significant difference (p>0,05). C 
– Representative immunofluorescence microscopy images of HepG2 cells infected 
with the different parasite lines 48h p.i. EEFs labeled with 2E6 primary antibodies 
(green) and cell nuclei labeled with Hoechst (blue). Scale bar (Cyan blue) = 100 
μm 
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Figure 14 - Immunofluorescence microscopy of exoerythrocytic forms in 
HepG2 cell culture 48h pi– A- PbGIMO EEFs labeled with 3D11 (green) for 
PbCS expression  and anti-UIS4 (red)(top row). Labeling with 2F2 (gold) for 
PvCS expression (bottom row). B -Pb(PvCS@UIS4) clone 2 EEFs labeled with 
3D11 (green) for PbCS expression  and anti-UIS4 (red)(top row). Labeling with 
2F2 (gold) for PvCS expression (bottom row). C - Pb(PvCS@UIS4) clone 4 
EEFs labeled with 3D11 (green) for PbCS expression  and anti-UIS4 (red)(top 
row). Labeling with 2F2 (gold) for PvCS expression (bottom row). Cell nuclei 
labeled with Hoechst (blue). Scale bar (Cyan blue) = 21 μm 
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microscope and all settings remained unchanged for each channel. As expected, and 
similarly to what was observed in the assays employing Huh7 cells, our results show 
that both Pb(PvCS@UIS4) clones express both PvCS and PbCS while PbGIMO 
expresses only PbCS (Fig.14). 
In vitro experiments with either Huh7 or HepG2 cells clearly indicated that liver-
stage development of Pb(PvCS@UIS4) parasites is similar to that of PbGIMO 
parasites. Pb(PvCS@UIS4) liver-stage parasite forms also seem to express both PbCS 
and PvCS to similar extents. This was expected due to the abundant expression of 
PbUIS4 during Plasmodium liver stage development (Fig.14, in red), therefore having 
PvCS being expressed under that promoter would lead to its expression during this 
stage.  
4.5 In vivo characterization of Pb(PvCS@UIS4) parasites 
Upon completion of the in vitro characterization of Pb(PvCS@UIS4) infectivity, 
we proceeded with the characterization of its infectivity and development in vivo.  
To evaluate in vivo infectivity and development of Pb(PvCS@UIS4), 9 C57BL/6 
mice (3 for each group) were infected i.v. with 30.000 sporozoites (3 experiments). At 
44h post infection, mice were sacrificed and their livers collected. A section of each 
liver was collected for microscopy analysis and the remaining was used for qRT-PCR 
quantification of Pb infection. 
4.5.1 Infection load quantified by qRT-PCR 
The first in vivo assay consisted in evaluating Pb(PvCS@UIS4) parasites ability 
to infect hepatocytes using an in vivo model. Using the RNA extracted from infected 
livers, the infection load was quantified by qRT-PCR. Quantification was carried out 
using the comparative threshold (cT) method, based on the ratio between the mouse 
HPRT as a housekeeping gene and the P. berghei 18S mRNA levels (2HPRT/218S) 
(Fig.15). The following results were obtained from 2 independent experiments. 
 
Figure 15- Determination of liver 
infection load by qRT-PCR– A total of 3 
mice were infected with each parasite 
(PbGIMO, Pb(PvCS@UIS4) clone 
2&4).Quantification of parasite liver load at 
44h post infection with 30.000 sporozoites. 
Results are expressed as means of the 
infection load and error bars represent 
standard error of the mean. Mann-Whitney 
test showed no significant differences 
between Pb(PvCS@UIS4) clones and 
PbGIMO. (p>0,05). 
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4.5.2 Infectivity and development analysis by immunofluorescence 
microscopy 
Pb(PvCS@UIS4) infectivity was also assessed by immunofluorescence 
microscopy. To this end, 50-μm sections of the livers collected from all 3 groups of 
mice were stained and analyzed by immunofluorescence microscopy. Liver slices were 
stained with anti-PbUIS4 antibodies (and the corresponding secondary antibody, anti-
goat Alexa Fluor 568). Liver slices were then observed on an Axiovert200M widefield 
microscope and the total number of EEFs was counted. Infectivity was calculated as 
the number of EEFs by total area of the liver slice (EEF/mm2); infectivity was then 
normalized to 100% of PbGIMO infection, with no significant differences found between 
them (p>0,05); [PbGIMO] 0,074 ± 0,0145 EEF/mm2; [Pb(PvCS@UIS4) clone 2] 0,0674 
± 0,0112 EEF/mm2 (91,44% of control);[Pb(PvCS@UIS4) clone 4] 0,0711 ± 0,0097 
EEF/mm2 (96,44 % of control) (Fig.16.A). 
Likewise, development was assessed as a function of EEF size. The following 
results were obtained from 3 independent experiments; [PbGIMO] 1082,4 ± 82,8 μm2; 
[Pb(PvCS@UIS4) clone 2] 917,7 ± 47,6 μm2; [Pb(PvCS@UIS4) clone 4] 1063,6 ± 48,4 
μm2 (Fig.16.B). These results are expressed as mean area of EEFs ± standard error of 
the mean. 
 
 
 
 
 
 
 
 
Figure 16 –In vivo liver-stage infectivity and development of 
Pb(PvCS@UIS4) assessed by immunofluorescence microscopy– A – 
Pb(PvCS@UIS4) clones infectivity 44h post infection, with 30.000 sporozoites, 
relative to control (PbGIMO). B – Parasite development inside mouse 
hepatocytes measured as EEF size 44h post infection. Results are expressed as 
mean of EEF area and error bars represent standard error of the mean. Mann-
Whitney test showed no significant difference between Pb(PvCS@UIS4) clones 
and PbGIMO (p>0,05). 
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4.5.3 In vivo expression assays 
To evaluate PbCS and PvCS expression by Pb(PvCS@UIS4) parasites in an in 
vivo model, 3 C57BL/6J mice (1 for each Pb(PvCS@UIS4) clone and PbGIMO) were 
infected with 100.000 sporozoites injected intravenously. At 44h post infection, livers 
were collected and 50 μm thick liver sections were prepared for immunofluorescence 
analysis. For each mouse, liver slices were incubated with either 3D11(anti-PbCS) + 
anti-UIS4 or 2F2 (anti-PvCS) + anti-UIS4 primary antibodies. In addition to secondary 
antibodies (Alexa-Fluor 488 anti-mouse IgG (for 3D11 and 2F2), Alexa-Fluor 568 anti-
goat IgG (for anti-UIS4)), liver slices were also incubated with Phaloidin Alexa-Fluor 
660 for cellular F-actin labeling and Hoechst for nuclei. Imaging was performed on a 
Zeiss LSM710 microscope and channel settings were kept unchanged for all images. 
As was shown in vitro, our results show that Pb(PvCS@UIS4) parasites also express 
both PbCS and PvCS during liver-stage (EEFs) in this in vivo model (Fig.17). 
               The in vivo experiments performed in C57BL/6J mice showed that 
Pb(PvCS@UIS4) parasites can infect and develop inside mouse hepatocytes to the 
same extent as the control parasite (PbGIMO). We could also observe that 
Pb(PvCS@UIS4) expresses both PbCS and PvCS as expected from this parasite. 
These last experiments conclude the pre-erythrocytic stage characterization of 
Pb(PvCS@UIS4) parasites. However, none of the experiments above have addressed 
Pb(PvCS@UIS4)‟s ability to cause blood-stage infection in mice. Thus, in order to 
address this, we decided to conduct a time course experiment of blood-stage 
development of the parasites. 
 
4.6 Characterization of blood-stage development of Pb(PvCS@UIS4) 
parasites 
             To characterize the ability of Pb(PvCS@UIS4) parasites to progress to blood-
stage forms and develop parasitemia in rodents, a total of nine mice (three for each 
parasite) were infected by i.v. injection of 30.000 sporozoites. This experiment is 
intended to determine whether Pb(PvCS@UIS4) merozoites can reach the 
bloodstream, infect red-blood cells and replicate to the same extent as wild type 
parasites. Blood smears were checked for parasitemias every day starting two days 
post-infection. All mice were kept in the same environment to avoid possible bias. As 
shown on Fig.18, the observed blood-stage development of all three groups was 
almost identical. These results show us that the presence of PvCS in Pb(PvCS@UIS4) 
parasites, does not seem to influence the parasite‟s capacity to exit hepatocytes and 
develop inside red blood cells. 
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Figure 17 - Immunofluorescence microscopy analysis of EEF forms on 
mouse livers, 44h post sporozoite infection– A- PbGIMO EEFs labeled with 
3D11 (green) for PbCS expression and anti-UIS4 (red) (top row). Labeling with 
2F2 (gold) for PvCS expression (bottom row). B -Pb(PvCS@UIS4) clone 2 EEFs 
labeled with 3D11 (green) for PbCS expression  and anti-UIS4 (red) (top row). 
Labeling with 2F2 (gold) for PvCS expression (bottom row). C - Pb(PvCS@UIS4) 
clone 4 EEFs labeled with 3D11 (green) for PbCS expression  and anti-UIS4 
(red)(top row). Labeling with 2F2 (gold) for PvCS expression (bottom row). Cell 
nuclei were labeled with Hoechst (blue) and cellular F-actin was labeled with 
phalloidin (white). Scale bar (Cyan blue) = 21 µm. 
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With this last experiment, we concluded the characterization of 
Pb(PvCS@UIS4) parasites during all of its developmental stages. No significant 
differences were observed between the fitness of both Pb(PvCS@UIS4) clones  and 
PbGIMO parasites during sporogonic, pre-erythrocytic and blood-stage development. 
Additionally, CS expression was also observed, showing that PbCS expression was 
identical between PbGIMO and Pb(PvCS@UIS4) parasites during sporogonic and pre-
erythrocytic stages while only Pb(PvCS@UIS4) parasites expressed PvCS. 
  
Figure 18–Time course of parasitemia in C57BL/6J mice infected by 
i.v. injection of 30.000 sporozoites– Three mice were infected with each 
parasite; PbGIMO, Pb(PvCS@UIS4) clone 2 and Pb(PvCS@UIS4) clone 
4. Parasitemias were checked daily. The results are expressed as means 
of the parasitemias for each infection group at each day. Vertical bars 
represent the standard error of the mean for each daily parasitemia check. 
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5. Discussion 
 
Malaria remains one of the most deadly infectious diseases worldwide, with no 
vaccine licensed so far. Despite many years of intense research, the most advanced 
vaccine candidate against P. falciparum malaria, RTS,S, has shown to confer only 
modest and short lasting protection.29 RTS,S is a subunit vaccine and consists on the 
administration of part of the P. falciparum CS protein fused to a carrier matrix and 
immunostimulants.27 As an alternative, other vaccination strategies are also in 
development, such as whole-organism vaccines. Studies using radiation-attenuated P. 
falciparum sporozoites have already proven that whole-organism vaccines can elicit 
effective and long-lasting protection against non-attenuated parasites in humans. 
However, whole-organism vaccination strategies that have been under development 
thus far rely on the use of human-infective Plasmodium as a vaccination agent and 
therefore present the risk of breakthrough infections, leading to pathology upon 
administration of the vaccine.33,36,43 The host lab proposed an alternative method to 
circumvent some of difficulties associated to previously proposed whole vaccination 
strategies against malaria: 
We proposed the use of P. berghei as a vaccination agent against human-
infective Plasmodium species. We hypothesize that this strategy can confer protection 
against infection with human malaria parasites through the induction of an 
heterologous immune response against conserved antigens between rodent and 
human malaria parasites, as well as serve as delivery platform of specific antigens from 
human infecting Plasmodium, namely the immunodominant CS protein. 
The phenomenon of cross-protection between different Plasmodium species 
has been previously reported in mice.54,59,60 Mice immunized with radiation-attenuated 
P. berghei sporozoites have shown to have a high level of protection against P. yoelii 
infections (79%) and vice-versa (63%).59 A different study showed that mice immunized 
with P. falciparum were protected against P. berghei infections.54 The immune 
responses responsible for heterologous protection in these cases were mainly CD8+ 
and CD4+ T cell-mediated.59–61 
In order to prove the validity of the proposed strategy, the host lab has 
demonstrated that P. berghei can infect and develop in human hepatocytes without 
manifestations of blood stage infection and that a P. berghei parasite expressing P. 
falciparum CS can elicit an immune response capable of recognizing and inhibiting P. 
falciparum parasites. 
Given the fact that P. vivax is the most widespread human-infective 
Plasmodium species, and that research on a vaccine against this parasite species is 
hampered by technical limitations, such as the inability to produce in vitro cultures and 
the unavailability of animal models62, we decided to use the P. berghei platform to 
express P. vivax CS in order to create P. berghei parasites that express P. vivax CS in 
addition to their endogenous PbCS protein, Pb(PvCS@UIS4). 
A previous study showed that chimeric P. berghei parasites which had PbCS 
central repeats replaced by PvCS central repeat region (Pb-Pv), could infect and 
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develop inside hepatocytes to the same extent as wild type P. berghei.63 Moreover, 
these parasites were shown to successfully present the introduced PvCs repeats on 
the sporozoite surface and during their hepatic development, in such a way that 
rendered them susceptible to neutralization by anti-PvCs sera.63 On the other hand, 
PvCS repeats in these parasites are flanked by PbCS termini regions and therefore 
lack the PvCS C-terminal and N-terminal regions, which have been shown to be 
responsible for both CS-specific and non-specific T cell responses.64–66 In light of this, 
we aimed to create a parasite that expresses the full PvCS in a way that is non-
disruptive to the parasite‟s development, in order to elicit both humoral and cellular 
responses against PvCS as well as heterologous protection against other P. vivax 
antigens. 
All the results presented in this thesis aimed to characterize and clarify any 
relevant features regarding the new vaccine candidate, Pb(PvCS@UIS4), throughout 
its life cycle. Firstly, after generating this new transgenic parasite, we were concerned 
about how different our PvCS sequence would be from the PvCS proteins found 
worldwide. Our analysis showed that the N-terminus and C-terminus regions of our 
PvCS sequence are almost totally conserved when compared to the reference PvCS 
sequences found in PlasmoDB. If the protein sequence was changed in any way, it 
could acquire a different conformation, preventing PvCS antigens from being properly 
recognized. As previously mentioned, the N-terminus and C-terminus regions of our 
PvCS sequence contain smaller regions that have been shown to be critical for the 
parasite invasion and protein conformational changes throughout the parasite‟s 
development, namely the TSR motif and region I. 46 Therefore, the integrity of these 
regions is very important in the context of the proposed vaccine candidate. On the 
other hand, and most importantly in the context of a vaccine candidate, our PvCS 
protein‟s central repeat region has the GDRA(A/D)GQPA repeat as its most prevalent 
repeat, identically to the most common type worldwide, the VK210 type; however, 
within the VK210 type of PvCS there is some variability in terms of repeat numbers 
(normally range between 9 and 18 repeats)47,51,52,57 and repeat sequences58. The last 
repeat sequence in the transgenic parasite used in this work appears to differ from the 
ones present on the database (GNGAGGQAA). However, the same repeat has 
previously been found in parasite population studies from Sri Lanka, in the same 
location as in the PvCS gene sequence amplified here.47 Despite the biological 
significance (if any) of this specific repeat remaining unknown, within the context of a 
vaccine candidate, repeat variability may represent an advantage as it contributes with 
one more P. vivax specific antigen for the immune system to recognize.  
During the mosquito stage characterization of Pb(PvCS@UIS4) we have 
observed that the development of these parasites inside the mosquito was similar to 
that of PbGIMO parasites, the “transfection motherline”. Like PbCS, the inserted CS 
protein, PvCS, is also expressed on sporozoites. Despite the fact that recent studies 
indicate that most CD8+ T cell immune responses are elicited during liver-stage 
infection and are essential for a long-lasting protection against infection32, the possible 
contribution given by pre-hepatic stages should not be overlooked. Our in vitro 
experiments, consisting of infecting Huh7 and HepG2 cells with live, freshly collected, 
sporozoites, allowed us to demonstrate that Pb(PvCS@UIS4) parasites have a 
capacity to invade and develop inside hepatocytes similar to that of PbGIMO parasites. 
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The same results were observed in vivo by injecting 30.000 sporozoites i.v. in 
C57BL/6J mice. In the context of vaccination it is important that the Pb(PvCS@UIS4) 
parasites develop as much and as long as possible inside the hepatocytes, as it has 
been shown that the further the parasites develop in the liver, the higher the overall 
CD8+ T cell response, and the more likely it is for a vaccine to elicit effective 
protection.32 A possible explanation for this may be due to the full antigenic unfold on 
non-attenuated parasites during liver-stage, which may not happen if the parasites are 
attenuated by radiation.43 In light of this, our vaccination approach may prove to be a 
better alternative to vaccine candidates with an early parasite arrest during liver-stage 
development, as Pb(PvCS@UIS4) parasites are not attenuated in any way and seem 
to have no impairment in liver-stage infection and development without leading to 
blood-stage infection in humans. Our in vitro and in vivo findings also show that 
Pb(PvCS@UIS4) parasites express PbCS and PvCS during liver stage infection 
(observed at 46h post infection). Both CS proteins seem to be expressed on the 
parasitophorous vacuole membrane (PVM). This shows that PvCS is being correctly 
translocated to the membrane, despite being expressed on a P. berghei background. 
When evaluating blood-stage development of the transgenic parasites, parasitemia 
developed similarly in mice infected with each of the three parasites (PbGIMO, 
Pb(PvCS@UIS4) clone 2 and 4), indicating that the insertion of PvCS has no impact on 
blood stage development for these parasites. No CS (or UIS4) expression is expected 
during blood-stage, therefore no expression assays were performed for this 
developmental stage. 
From various immunization studies with the RTS,S vaccine, it became evident 
that, the CS protein can elicit a significant degree of protection against Plasmodium 
infection. The protection elicited is mainly antibody and CD4+ T cell mediated and none 
of the individuals vaccinated were protected six months after immunization.30,31 Despite 
CD4+ T cell and antibody responses being able protect against malaria, these have 
shown to not be sufficient  to achieve long term protection against a new infection.31 On 
the other hand, human trials with P. falciparum irradiated sporozoites, showed some 
degree of CD8+ T cell mediated response against CS.35 These two studies together 
suggest that whether or not the CS is presented within the context of a whole-organism 
influences the type of cellular response elicited against it. 
All the efforts in creating vaccination strategies against malaria provided 
valuable insights on what type of responses seem to be essential to successfully elicit 
immune protection against Plasmodium infections. By employing Pb(PvCS@UIS4) 
sporozoites we believe to have overcome safety limitations of using human-infective 
Plasmodium species as a vaccination agent. Moreover, protection against malaria has 
shown to be possible through various cellular and humoral responses. With 
Pb(PvCS@UIS4) sporozoites, we believe that it is possible to elicit a strong and long-
lasting immunity against P. vivax infections as a result of the summation of P. vivax-
specific and non-specific cellular and humoral responses against PvCS and 
heterologous antigens present on P. berghei.  
A number of questions remain open at the end of this study: 
- Are Pb(PvCS@UIS4) parasites able to trigger an immune response against P. vivax?  
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- What kinds of response are elicited (cellular/humoral)? 
- Are these responses able to recognize P. vivax parasites and inhibit infection? 
- Are the responses elicited by Pb(PvCS@UIS4), able to protect against P. vivax 
infections in humans? 
- Which responses are the main effectors of that protection? (The ones against PvCS 
or against P. berghei heterologous epitopes)? 
  
One possible way to tackle these questions would be through the use of an 
immunization protocol in mice similar to the ones performed on the “live-parasite 
immunization under antimalarial therapy studies” in mice67, with Pb(PvCS@UIS4) 
sporozoites and concomitant administration of chloroquine. After the immunization 
protocol is concluded, mice would be sacrificed and their blood and spleen collected. In 
order to determine if there is a humoral response capable of recognizing PvCS, ELISA 
analyses of the collected blood sera using PvCS central repeats as “bait” could be 
performed. Additionally, using the collected spleens, ELISpot analyses could be 
performed in order to detect specific cellular responses against P. vivax parasites and 
P. berghei parasites. This would provide an indication of what type of responses may 
be triggered in a real immunization scenario. 
In order to know whether or not the immune responses elicited by 
Pb(PvCS@UIS4) parasites are able to recognize P. vivax, an immunofluorescence 
assay could be performed using sera from Pb(PvCS@UIS4)-immunized mice on 
immobilized P. vivax sporozoites. Additionally, to determine if these responses are able 
to inhibit infection, serum from Pb(PvCS@UIS4) immunized mice could be used to 
incubate with P. vivax sporozoites; these sporozoites would then be used to infect liver-
humanized mice and livers analyzed 48h post infection in order to determine whether 
or not the serum was able to inhibit sporozoite invasion. 
The last two questions, however, would require this vaccine candidate to reach 
human trials. In order to tackle those, an identical immunization protocol as previously 
established for clinical trials performed with a vaccine candidate based on the 
administration radiation-attenuated P. falciparum sporozoites36 could be applied. 
Performing a challenge with P. vivax in humans can be difficult, as P. vivax can 
develop into hypnozoites, which could lead to relapses later on. This way, challenge 
with P. vivax should be performed with a primaquine-sensitive strain, so that 
hypnozoites can be effectively eliminated, without leading to further complications. 
After challenge with P. vivax, human volunteers should be monitored for parasitemia to 
assess whether or not they were protected against P. vivax malaria. We could also 
perform an ELISA test to assess if the same type of humoral recognition occurs in 
humans. Moreover, P. vivax cellular immune responses should be assessed before 
and after immunization in both protected and non-protected individuals to assess the 
kind of responses that are responsible for protection against P. vivax with our vaccine 
candidate. These are only a few examples of experiments that would answer some of 
the open questions left after this characterization. 
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In conclusion, the results presented here demonstrate that Pb(PvCS@UIS4) 
parasites can develop normally throughout its life cycle ,expressing an exogenous 
PvCS as well as their endogenous PbCS, without altering the parasite‟s fitness. When 
taken together, the results obtained with Pb(PvCS@UIS4) and the former 
Pb(PfCS@UIS4) parasites strongly suggest that this vaccination strategy represents a 
viable and safe alternative to the already existing vaccine candidates against human-
infective Plasmodium species. Based on results obtained from several studies, we 
believe that delivering a CS protein from a human malaria parasite on the P. berghei 
platform may confer a great advantage in the context of a vaccine as it is the 
immunodominant protein on the sporozoite‟s surface. However, P. berghei can be used 
as a platform to express other antigens found relevant for vaccination, such as 
antigens with relevant functions in the blood-stage development or transmission of 
Plasmodium parasites. On the other hand, as previously mentioned, several additional 
experiments are still required in order to understand the nature of the immune 
responses induced by these vaccine candidates, before being able to proceed to 
human trials. 
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7. Appendix section 
Appendix-1. Sequences of primers used. 
 
Primer name/nº Primer sequence 
uma1494 AATTTAGTGGGATCCATATGC 
uma1497 TATAATTCATTATGAGTAGTGTAATTCAG 
uma1654 GCAAAGTGAAGTTCAAATATG 
uma1655 GAAATCGCAAACATAAGTATC 
uma1901 GTTCGCTAAACTGCATCGTC 
uma1902 GTTTGAGGTAGCAAGTAGACG 
P. berghei 18S rRNA Forward AAGCATTAAATAAAGCGAATACATCCTTAC 
P. berghei 18S rRNA Reverse GGAGATTGGTTTTGACGTTTATGTG 
HPRT Forward TTTGCTGACCTGCTGGATTAC 
HPRT Reverse CAAGACATTCTTTCCAGTTAAAGTTG 
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Appendix -2. Consensus sequences from plasmids (With PvCS@UIS4 
cassette) obtained from transformed bacteria before transfection. 
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Appendix 3. Alignment Blast between our PvCS sequence and PvCS 
reference sequences 
 
Supplementary figure 1: Consensus alignment between the PvCS sequences 
present on plasmids obtained from different transformed bacteria (Colony 5, 6, 13, 
14, 15 and 17). PvCS sequence from colony 17 (red rectangle) was the one used for 
transfection as it is the one with highest homology to the reference sequence 
(PlasmoDB) PVX_119355. 
 
 
 
57 
 
 
 
 
 Supplementary figure 2: Alignment Blast between our PvCS sequence and 
PvCS reference sequences present on PlasmoDB; Pv_Sal1_chr08 (Salvador), 
BrazilI (Brazil) and IndiaVII (India). 
 
